Skip to content
← All treatment topics

TREATMENT READING

Neuroblastoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

73 sections
  1. Response to treatment
  2. Treatment era
  3. Special Considerations for the Treatment of Children With Cancer
  4. Treatment Option Overview for Neuroblastoma
  5. Principles of Surgery
  6. Principles of Radiation Therapy
  7. Treatment of Spinal Cord Compression
  8. Surveillance During and After Treatment
  9. Evaluation of Disease Response
  10. Revised International Neuroblastoma Response Criteria (INRC)
  11. Treatment of Non–High-Risk Neuroblastoma
  12. Low-Risk Neuroblastoma
  13. Treatment options for low-risk neuroblastoma
  14. Surgery followed by observation
  15. Observation with or without biopsy
  16. Chemotherapy with or without surgery
  17. Treatment options under clinical evaluation
  18. Intermediate-Risk Neuroblastoma
  19. Treatment options for intermediate-risk neuroblastoma
  20. Chemotherapy with or without surgery
  21. Surgery and observation (in infants)
  22. Radiation therapy
  23. Treatment options under clinical evaluation
  24. Treatment of High-Risk Neuroblastoma
  25. Treatment Options for High-Risk Neuroblastoma
  26. Chemotherapy, surgery, tandem cycles of myeloablative therapy and HSCT, radiation therapy, and dinutuximab, with GM-CSF and isotretinoin
  27. Induction phase
  28. Consolidation phase
  29. Postconsolidation phase
  30. Treatment Options Under Clinical Evaluation
  31. Treatment of INSS Stage 4S and INRG Stage MS Neuroblastoma
  32. Treatment Options for Stage 4S/MS Neuroblastoma
  33. Observation with supportive care
  34. Chemotherapy
  35. Surgery
  36. Radiation therapy
  37. Treatment Options Under Clinical Evaluation
  38. Treatment of Recurrent or Refractory Neuroblastoma
  39. Prognostic Factors in Patients With Recurrent Neuroblastoma
  40. Recurrent Neuroblastoma in Patients Initially Classified as Low Risk
  41. Locoregional recurrence
  42. Metastatic recurrence or disease refractory to standard treatment
  43. Recurrent Neuroblastoma in Patients Initially Classified as Intermediate Risk
  44. Locoregional recurrence
  45. Metastatic recurrence
  46. Recurrent or Refractory Neuroblastoma in Patients Initially Classified as High Risk
  47. Recurrent Neuroblastoma in the Central Nervous System
  48. Treatment Options Under Clinical Evaluation for Recurrent or Refractory Neuroblastoma
  49. Certain factors affect prognosis (chance of recovery) and treatment options.
  50. Treatment of neuroblastoma is based on risk groups.
  51. Sometimes neuroblastoma does not respond to treatment or comes back after treatment.
  52. Treatment Option Overview
  53. Key Points
  54. There are different types of treatment for children with neuroblastoma.
  55. Children with neuroblastoma should have their treatment planned by a team of doctors who are experts in treating childhood cancer, especially neuroblastoma.
  56. The following types of treatment may be used:
  57. Observation
  58. Surgery
  59. Chemotherapy
  60. Radiation therapy
  61. High-dose chemotherapy and radiation therapy with stem cell rescue
  62. Iodine 131-MIBG therapy
  63. Targeted therapy
  64. Other drug therapy
  65. Immunotherapy
  66. New types of treatment are being tested in clinical trials.
  67. Treatment for neuroblastoma causes side effects and late effects.
  68. Follow-up care may be needed.
  69. Treatment of Low-Risk Neuroblastoma
  70. Treatment of Intermediate-Risk Neuroblastoma
  71. Treatment of High-Risk Neuroblastoma
  72. Treatment of Stage MS Neuroblastoma
  73. Treatment of Recurrent Neuroblastoma

Health professional · General Information About Neuroblastoma / Prognostic Factors

Response to treatment

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Response to treatment has been associated with outcome. In patients with intermediate-risk disease who had a poor response to initial therapy in the COG ANBL0531 (NCT00499616) study, 6 of 20 patients subsequently developed progressive or recurrent disease, and one patient died.[102]

Sources: ANBL0531 (NCT00499616) · 102

In patients with high-risk disease, the persistence of neuroblastoma cells in bone marrow after induction chemotherapy is associated with a poor prognosis. Sensitive techniques that detect minimal residual disease may be used to assess prognosis.[108-110] For example, detection of RNA transcripts expressed by neuroblastoma cells (in the bone marrow) after initial induction chemotherapy in children with high-risk neuroblastoma has been associated with significantly inferior EFS and OS.[111]

Sources: 108 · 110 · 111

Similarly, the persistence of MIBG-avid tumor, measured as Curie score greater than 2 after completion of induction therapy, predicts a poor prognosis for patients with MYCN-nonamplified high-risk tumors. A Curie score greater than 0 after induction therapy is associated with a worse outcome for high-risk patients with MYCN-amplified disease.[112,113] An analysis of North American patients who went on to receive tandem transplants showed that patients with Curie scores greater than 0 at the end of induction therapy had inferior EFS rates.[114] For more information about Curie scoring, see the Curie and SIOPEN scoring methods section.

Sources: 112 · 113 · 114 · Curie and SIOPEN scoring methods

In an analysis of patients from four consecutive COG high-risk trials, an end-induction response of partial response (PR) or better, according to the 1993 International Neuroblastoma Response Criteria,[64] was significantly associated with higher EFS and OS. On multivariable analysis (n = 407), the absence of 11q loss of heterozygosity (LOH) was the only factor that remained significantly associated with PR or better (OR, 1.962 vs. 11q LOH; 95% CI, 1.104–3.487; P = .0216).[115]

Sources: 64 · 115

A treatment-associated decrease in mitosis and an increase in histological differentiation of the primary tumor are also prognostic of response.[116]

Sources: 116

The accuracy of prognostication based on decrease in primary tumor size is less clear. In a study conducted by seven large international centers, 229 high-risk patients were treated in a variety of ways. Treatment included chemotherapy, surgical removal of the primary tumor, radiation to the tumor bed, high-dose myeloablative therapy plus stem cell transplant, and, in most cases, isotretinoin and anti-GD2 antibody immunotherapy enhanced by cytokines. Primary tumor response was measured after induction chemotherapy in three ways: as 30% or greater reduction in the longest dimension, 50% or greater reduction in tumor volume, or 65% or greater reduction in tumor volume (calculated from three tumor dimensions, a conventional radiological technique). The measurements were performed at diagnosis and after induction chemotherapy before primary tumor resection. None of the methods of measuring primary tumor response at end of induction chemotherapy predicted survival.[117]

Sources: 117

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · General Information About Neuroblastoma / Prognostic Factors

Treatment era

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Between 1975 and 2020, the 5-year survival rate for neuroblastoma in the United States increased from 86% to 93% for children younger than 1 year and from 34% to 83% for children aged 1 to 14 years.[2,3] The 5-year relative survival rate for all infants and children with neuroblastoma increased from 46% when diagnosed between 1974 and 1989 to 71% when diagnosed between 1999 and 2005.[119] More recent estimates from 2014 to 2020 show an even higher 5-year relative survival rate of approximately 85% for infants and children younger than 15 years.[2] These statistics can be misleading because of the extremely heterogeneous prognosis based on the patient's age, stage, and biology. However, studies demonstrate a significant improvement in survival for high-risk patients diagnosed and treated between 2000 and 2019, compared with patients diagnosed from 1990 to 1999.[120,121] For more information, see Table 1. Similarly, the COG ANBL0531 (NCT00499616) study found equivalent outcomes for many subsets of intermediate-risk children who were treated with substantially reduced chemotherapy, compared with the earlier COG-A3961 (NCT00003093) study.[102]

Sources: 2 · 3 · 119 · 2 · 120 · 121 · Table 1 · ANBL0531 (NCT00499616) · COG-A3961 (NCT00003093) · 102

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Transplant surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Health professional

Treatment Option Overview for Neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Generally, treatment of neuroblastoma is based on whether the tumor is classified as non-high risk (low or intermediate risk) or high risk. Because 5-year survival rates are generally 90% or higher, the goal of treatment for non–high-risk disease is to cure the disease with minimal toxicity. Outcomes for patients with high-risk disease have improved over time with the use of increasingly intensive multimodal therapy, but they remain suboptimal.

Low risk. For patients with low-risk tumors, the approach is either observation or resection, with chemotherapy restricted to symptomatic patients with low-risk biology. The 5-year overall survival (OS) rate was 98% for the low-risk patients among more than 5,000 patients enrolled in the Children's Oncology Group (COG) ANBL00B1 (NCT00904241) biology study.[1]

Sources: ANBL00B1 (NCT00904241) · 1

Intermediate risk. For patients with intermediate-risk tumors, chemotherapy is often given before definitive resection. Multiagent chemotherapy consisting of doxorubicin, cyclophosphamide, a platinum drug, and etoposide is used. The number of chemotherapy cycles is based on clinical and tumor biological risk factors and response to therapy.[2] The goal of chemotherapy is to deliver a sufficient duration of chemotherapy (with or without surgery) to achieve at least a partial response (at least 50% reduction of soft tissue masses) and resolution of metastatic disease.[2] In some studies, select patients have been observed without undergoing chemotherapy or attempted resection. The 5-year OS rate was about 95% for the intermediate-risk patients among more than 5,000 patients enrolled in the COG ANBL00B1 (NCT00904241) biology study.[1] In the COG ANBL0531 (NCT00499616) study, the duration and intensity of chemotherapy was decreased in several subsets of intermediate-risk children to further diminish side effects; no declines in outcomes were seen.[2,3]

Sources: 2 · 2 · ANBL00B1 (NCT00904241) · 1 · ANBL0531 (NCT00499616) · 2 · 3

High risk. For high-risk patients, treatment has intensified to include chemotherapy, surgery, radiation therapy, myeloablative therapy and hematopoietic stem cell transplant (HSCT), isotretinoin, and immunotherapy, resulting in 5-year survival rates of 62%.[1] Statistically significant improvement in event-free survival (EFS) was observed in a randomized phase III COG study (ANBL0532 [NCT00567567]) with tandem cycles of myeloablative therapy and HSCT, compared with a single cycle of myeloablative therapy and HSCT. The 3-year EFS rate for patients who received tandem transplants was superior (P = .006) to the EFS rate for patients who received single transplants, although OS was not statistically different. In this study, a large proportion of patients were not randomized.[4][Level of evidence A1] For more information, see the Consolidation phase section.

Sources: 1 · ANBL0532 [NCT00567567] · 4 · Level of evidence A1 · Consolidation phase

Table 6 summarizes the treatment options for patients with low-risk, intermediate-risk, and high-risk disease.

Sources: Table 6

Table 6. Treatment Options for Neuroblastoma
COG Risk-Group AssignmentTreatment Options
COG = Children's Oncology Group; GM-CSF = granulocyte-macrophage colony-stimulating factor; HSCT = hematopoietic stem cell transplant.
Low-Risk NeuroblastomaSurgery followed by observation.
Observation with or without biopsy.
Chemotherapy with or without surgery (for symptomatic disease or unresectable progressive disease after surgery).
Radiation therapy (only for emergency therapy).
Intermediate-Risk NeuroblastomaChemotherapy with or without surgery.
Surgery and observation (in infants).
Radiation therapy (for progressive disease, if needed).
High-Risk NeuroblastomaA regimen of chemotherapy, surgery, tandem cycles of myeloablative therapy and HSCT, radiation therapy, and dinutuximab, with GM-CSF and isotretinoin.
Stage 4S NeuroblastomaObservation with supportive care (for asymptomatic patients with favorable tumor biology).
Chemotherapy (for symptomatic patients, those with unfavorable tumor biology, and infants aged <3 months).
Surgery (rarely, for patients with hepatomegaly that compromises the kidney or other abdominal organs).
Radiation therapy (rarely, for patients with symptoms related to hepatomegaly from metastatic disease).

Sources: Surgery followed by observation · Observation with or without biopsy · Chemotherapy with or without surgery · Radiation therapy · Chemotherapy with or without surgery · Surgery and observation · Radiation therapy · A regimen of chemotherapy, surgery, tandem cycles of myeloablative therapy and HSCT, radiation therapy, and dinutuximab, with GM-CSF and isotretinoin · Observation with supportive care · Chemotherapy · Surgery · Radiation therapy

Health professional · Treatment Option Overview for Neuroblastoma

Principles of Surgery

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

In patients without metastatic disease, the standard of care is to perform an initial surgery. This surgery aims to accomplish the following, based on the disease stage and the risk group:

Obtain tissue for diagnosis. Incisional or core biopsy only is recommended for patients with L2 disease,[5][Level of evidence C1] and an up-front resection should generally not be attempted. For more information about image-defined risk factors (IDRFs), see the International Neuroblastoma Risk Group Staging System (INRGSS) section.

Sources: 5 · Level of evidence C1 · International Neuroblastoma Risk Group Staging System (INRGSS)

Obtain tissue for diagnosis. Incisional or core biopsy only is recommended for patients with L2 disease,[5][Level of evidence C1] and an up-front resection should generally not be attempted. For more information about image-defined risk factors (IDRFs), see the International Neuroblastoma Risk Group Staging System (INRGSS) section.

Either incisional biopsy or percutaneous core needle biopsy are acceptable for patients with L2 disease. In a multi-institutional retrospective study, there was no significant difference in the ability to accurately obtain a primary diagnosis by percutaneous core needle biopsy compared with incisional biopsy (95.7% vs. 98.9%, P = .314) or determine MYCN copy number (92.4% vs. 97.8%; P = .111). The yield for loss of heterozygosity and tumor ploidy was lower with percutaneous core needle biopsy (dependent on the number of cores/volume of tissue obtained) than with incisional biopsy (56.1% vs. 90.9%, P < .05; and 58.0% vs. 88.5%, P < .05). Complications did not differ between the groups.[6][Level of evidence C1]

Sources: 6 · Level of evidence C1

Near-total or total resection (80%–90%) of the primary tumor is recommended based on stage.

Near-total or total resection (80%–90%) of the primary tumor is recommended based on stage.

This is standard for patients with low-risk (excluding prenatally diagnosed infants who are candidates for observation) and intermediate-risk disease. In patients with L1 tumors (defined as having no image-defined surgical risk factors), the tumors are resectable with low risk of nephrectomy or life-threatening complications. Unilateral adrenal gland primary tumors, thoracic L1 disease, or neck L1 disease should be resected up front (per the surgeons’ discretion).[5][Level of evidence C1]

Sources: 5 · Level of evidence C1

Minimally invasive surgery may be considered in highly selected patients with neuroblastoma if it is performed by a pediatric surgical oncologist who has expertise using this technique.[7][Level of evidence C1]; [8,9]

Sources: 7 · Level of evidence C1 · 8 · 9

The COG reported that expectant observation in infants younger than 6 months with small (L1) adrenal masses resulted in an excellent EFS and OS while avoiding surgical intervention in a large majority of patients.[10] According to the surgical guidelines described in the intermediate-risk neuroblastoma clinical trial (ANBL0531 [NCT00499616]), the primary tumor is not routinely resected in patients with 4S neuroblastoma. German studies of selected groups of patients have biopsied tissue and observed infants with both L1 and L2 tumors without MYCN amplification, avoiding additional surgery and chemotherapy in most patients.[11]

Sources: 10 · ANBL0531 [NCT00499616] · 11

Whether there is any advantage to gross-total resection (>90%) of the primary tumor mass after chemotherapy in patients older than 18 months with stage 4 disease remains controversial.[12-17] A meta-analysis of patients with stage 3 versus stage 4 neuroblastoma, at all ages combined, found an advantage for gross-total resection (>90%) over subtotal resection in stage 3 neuroblastoma only.[18] A small study suggested that after neoadjuvant chemotherapy, completeness of resection was affected by the number of IDRFs remaining.[19] When an experienced surgeon performed the procedure, a 90% or greater resection of the primary tumor in stage 4 neuroblastoma resulted in a higher local control rate, but it did not have a statistically significant impact on OS.[20]

Sources: 12 · 17 · 18 · 19 · 20

For more information about IDRFs, see the International Neuroblastoma Risk Group Staging System (INRGSS) section.

Sources: International Neuroblastoma Risk Group Staging System (INRGSS)

Health professional · Treatment Option Overview for Neuroblastoma

Principles of Radiation Therapy

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

In the current treatment paradigm, radiation therapy for patients with low-risk or intermediate-risk neuroblastoma is reserved for symptomatic life-threatening or organ-threatening tumor bulk that did not respond rapidly enough to chemotherapy. Common situations in which radiation therapy is used in these patients include the following:

Infants aged 60 days and younger with stage 4S and marked respiratory compromise from liver metastases that has not responded to chemotherapy.[21]

Sources: 21

For patients with spinal cord compression. However, most patients are treated with chemotherapy or neurosurgical intervention because of the responsiveness of neuroblastoma to chemotherapy and the potentially devastating late effects of radiation therapy in young children.[22]

Sources: 22

Radiation therapy has become part of the standard of care for patients with high-risk disease and is usually delivered after high-dose chemotherapy and stem cell rescue. For more information, see the Treatment of High-Risk Neuroblastoma section.

Sources: Treatment of High-Risk Neuroblastoma

Limiting the use of radiation therapy in infants with neuroblastoma (who generally have non–high-risk disease) is supported by long-term follow-up data from the Childhood Cancer Survivor Study. This study demonstrated higher rates of second malignant neoplasms and significant chronic health conditions in infants who were treated with radiation therapy.[23][Level of evidence C1]

Sources: 23 · Level of evidence C1

Health professional · Treatment Option Overview for Neuroblastoma

Treatment of Spinal Cord Compression

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Spinal cord compression is considered a medical emergency. Patients receive immediate treatment because neurological recovery is more likely when symptoms are present for a relatively short time before diagnosis and treatment. Recovery also depends on the severity of neurological defects (weakness vs. paralysis). Neurological outcome appears to be similar whether cord compression is treated with chemotherapy, radiation therapy, or surgery, although radiation therapy is used less frequently than in the past.

The completed COG neuroblastoma clinical trials recommended immediate chemotherapy for cord compression in low-risk or intermediate-risk patients.[22,24,25] In a single study in this setting looking at the effect of glucocorticoids on neurological outcome, treatment was associated with improved early symptom relief. However, glucocorticoids did not prevent late residual impairment.[25]

Sources: 22 · 24 · 25 · 25

Children with severe spinal cord compression that does not promptly improve or those with worsening symptoms may benefit from neurosurgical intervention. Laminectomy may result in later kyphoscoliosis and may not eliminate the need for chemotherapy.[22,24,25] Osteoplastic laminotomy, a procedure that does not remove bone, was thought to lessen spinal deformity. Osteoplastic laminotomy may be associated with a lower incidence of progressive spinal deformity requiring fusion, but there is no evidence that functional neurological deficit is improved with laminoplasty.[26]

Sources: 22 · 24 · 25 · 26

The burden of long-term health problems in survivors of neuroblastoma with intraspinal extension is high. In a systematic review of 28 studies of treatment and outcome of patients with intraspinal extension, the severity of the symptoms at diagnosis and the treatment modalities were most associated with the presence of long-term health problems. In particular, the severity of neurological motor deficits was most likely to predict neurological outcome.[27] The severity of motor deficits at diagnosis is associated with spinal deformity and sphincter dysfunction at the end of follow-up, while sphincter dysfunction at diagnosis was correlated with long-term sphincter problems.[28] This supports the initiation of treatment before symptoms have deteriorated to complete loss of neurological function.

Sources: 27 · 28

In a series of 34 infants with symptomatic epidural spinal cord compression, both surgery and chemotherapy provided unsatisfactory results once paraplegia had been established. The frequency of grade 3 motor deficits and bowel dysfunction increased with a longer symptom duration interval. Most infants with symptomatic epidural spinal cord compression developed sequelae, which were severe in about one-half of patients.[29]

Sources: 29

An analysis of patients with intermediate-risk disease treated in the COG ANBL0531 [NCT00499616] study included 92 patients with intraspinal disease.[30] Of these patients, 42 (46%) were symptomatic. Among patients who were symptomatic, motor symptoms and bowel/bladder symptoms resolved completely in 73% and 88% of patients, respectively. Laminectomy or laminoplasty was performed in 22 of 42 symptomatic patients and was not significantly associated with improvements in symptoms.

Sources: ANBL0531 [NCT00499616] · 30

Health professional · Treatment Option Overview for Neuroblastoma

Surveillance During and After Treatment

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Although the role of surveillance imaging for detection of neuroblastoma relapse has not been well studied, most patients will undergo regular imaging tests after completing therapy. Many patients who relapse are asymptomatic, and relapse is detected on surveillance evaluations. Factors such as risk stratification, disease sites, biomolecular markers, and cumulative radiation dose may be considered in surveillance after treatment.[31-33]

Sources: 31 · 33

One series included 154 patients with high-risk neuroblastoma who had a complete or very good partial response and subsequently had relapsed disease. The study found that 113 of the patients (73%) had asymptomatic relapse, while only 41 (27%) presented with symptoms. Metaiodobenzylguanidine (MIBG) scans were the most reliable study to detect asymptomatic relapse.[32]

Sources: 32

In another series of 183 patients diagnosed with neuroblastoma, 50 patients experienced recurrence or progression. Relapsed disease was detected in most patients by symptoms/examination, MIBG scan, urinary catecholamines, and/or x-rays or ultrasonography.[33]

Sources: 33

Of the 50 patients, 37 had clinically evident or measurable disease detected by x-ray, ultrasonography, or urinary catecholamines. The addition of MIBG scanning identified eight additional recurrences.

The cross-sectional imaging (computed tomography [CT]/magnetic resonance imaging) was only required to identify 10% of cases (5 of 50).

Thirty-two of the 50 relapses (64%) were detected by scheduled surveillance investigations, and 18 of the 50 relapses (36%) were detected because of new symptoms and/or history.

Twenty-three of 50 relapses were associated with new concerning symptoms and/or examination. As a result, 18 of 50 patients had earlier-than-planned imaging performed, 17 of whom had new lesions that corresponded to the symptoms or examination. Seventeen of the 18 patients were high risk at diagnosis.

Cross-sectional imaging with CT scans is controversial because of the amount of radiation received and the low proportion of relapses detected with this modality.[33]

Sources: 33

Health professional · Treatment Option Overview for Neuroblastoma

Evaluation of Disease Response

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Evaluation of response is critical for the management of individual patients, but it is also necessary for comparing results of clinical trials. Given the complexities of a disease with propensity for bone and bone marrow metastasis, international consensus criteria have been developed and refined over the last several decades. The current version of these International Neuroblastoma Response Criteria (INRC) is presented below.

Health professional · Treatment Option Overview for Neuroblastoma

Revised International Neuroblastoma Response Criteria (INRC)

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

INRC is used to assess response to treatment.[34-36] Overall response in the revised INRC integrates tumor response in three components: primary tumor, soft tissue and bone metastases, and bone marrow. Primary and metastatic soft tissue sites are assessed using Response Evaluation Criteria in Solid Tumors (RECIST) and iodine I 123 (123I) MIBG scans or fluorine F 18-fludeoxyglucose (18F-FDG) positron emission tomography (PET) scans if the tumor is MIBG nonavid. 123I-MIBG scans, or 18F-FDG PET scans for MIBG-nonavid disease, replaced Technetium Tc 99m (99mTc) diphosphonate bone scintigraphy for osteomedullary metastasis assessment. Bone marrow is assessed by histology with or without immunohistochemistry and cytology or immunocytology. Bone marrow with 5% or less tumor involvement is classified as minimal disease. Urinary catecholamine levels are not included in response assessment. Overall response is defined as complete response, partial response, minor response, stable disease, or progressive disease.[36]

Sources: 34 · 36 · 36

The overall INRC response criteria are defined as follows:[34,35]

Sources: 34 · 35

Complete Response: No evidence of disease, including resolution of MIBG uptake (or PET scan positivity in MIBG non-avid disease) in any location of soft tissue or bone, with less than 10 mm remaining on 3-D imaging of primary tumor; target lymph nodes less than 15 mm in short dimension; and no histological tumor in two bone marrow biopsies and two bone marrow aspirates sampled at one time point.

Partial Response: 30% or more decrease in longest diameter of primary site and at least 30% decrease in sum of diameters of nonprimary soft tissue metastases (soft tissue sites may still be avid); and at least a 50% reduction in absolute MIBG bone score or a 50% or greater reduction in number of 18F-FDG PET-avid bone lesions; and bone marrow with 0% to 5% tumor; and no new lesions.

Minor Response: Partial response or complete response of at least one component of disease, but at least one other component with stable disease and no component with progressive disease.

Progressive Disease: Any new lesion; increase in longest diameter in any measurable soft tissue lesion by 20% with at least 5 mm absolute increase; previous negative bone marrow now positive for at least 5% tumor or previous positive bone marrow that increases twofold in tumor percentage and increases to more than 20% tumor; any new soft tissue lesion that is MIBG (or 18F-FDG PET) avid or positive by biopsy; a new avid bone site; or increase in relative MIBG score to at least 1.2.

Stable Disease: Stable disease in one component with no better than stable disease or no involvement at other two components. No components meet criteria for progressive disease or partial response.

Care should be taken in interpreting the development of metastatic disease in an infant who was initially considered to have stage 1 or 2 disease. If the pattern of metastases in such a patient is consistent with a 4S pattern of disease (involvement of skin, liver, and/or bone marrow, the latter less than 10% involved), these patients are not classified as having progressive/metastatic disease, which would typically be a criterion for removal from protocol therapy. Instead, these patients are managed as stage 4S patients.

Controversy exists regarding the necessity of measuring the primary tumor response in all three dimensions or whether the single longest dimension, as in RECIST tumor response determination, is equally useful.[37] The latter has been adopted for use in the INRC.

Sources: 37

Health professional

Treatment of Non–High-Risk Neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Approximately one-half of all newly diagnosed patients with neuroblastoma have non–high-risk disease (i.e., low and intermediate risk).[1] Since these patients have excellent survival, with 5-year survival rates higher than 95% for patients with low-risk disease and between 90% and 95% for patients with intermediate-risk disease, the goal of therapy for these patients is to cure the disease with minimal toxicity.

Sources: 1

The staging system, risk classification system, and response criteria definitions for neuroblastoma have evolved over the past 20 years. As a result, published results from clinical trials for patients with non–high-risk neuroblastoma from the past used different staging systems (International Neuroblastoma Staging System) and response criteria or protocol-specific response criteria, making it difficult to compare trial results.

Health professional · Treatment of Non–High-Risk Neuroblastoma

Low-Risk Neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

The success of previous Children's Oncology Group (COG) clinical trials has contributed to the continued reduction in therapy for select patients with neuroblastoma. According to the COG risk categorization, patients with low-risk disease generally have low-stage disease (International Neuroblastoma Risk Group [INRG] stage L1) and the tumors are MYCN-nonamplified, hyperdiploid, and have favorable histology (FH). For more information about the COG risk categories, see Table 3.

Sources: Table 3

For more information about low-stage disease, see the Treatment of INSS Stage 4S and INRG Stage MS Neuroblastoma section.

Sources: Treatment of INSS Stage 4S and INRG Stage MS Neuroblastoma

Health professional · Treatment of Non–High-Risk Neuroblastoma / Low-Risk Neuroblastoma

Treatment options for low-risk neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Surgery, by an experienced surgeon, is the treatment of choice for patients with low-risk, INRG stage L1 tumors. The exception is for patients who are younger than 6 months with isolated adrenal masses with maximum diameter smaller than 3.1 cm if solid, or 5 cm if at least 25% of the mass is cystic. For these patients, observation without biopsy is the recommended approach. If the biology is confirmed to be favorable, residual disease after surgery is not considered a risk factor for relapse and chemotherapy is not indicated. Several studies have shown that patients with favorable biology and residual disease have excellent outcomes, with event-free survival (EFS) rates exceeding 90% and overall survival (OS) rates ranging from 99% to 100%.[2,3]

Sources: 2 · 3

In patients with INRG stage MS disease who are asymptomatic and have tumors with favorable biology, observation is the preferred approach.

Some patients with presumed neuroblastoma have been observed without biopsy. The COG is studying this strategy further in the ANBL1232 (NCT02176967) trial (closed to accrual).[4,5]

Sources: ANBL1232 (NCT02176967) · 4 · 5

Treatment options for low-risk neuroblastoma include the following:

Surgery followed by observation (INRG stage L1 or MS).

Sources: Surgery followed by observation

Observation with or without biopsy.

Sources: Observation with or without biopsy

Observation with or without biopsy.

Observation without biopsy (for perinatal neuroblastoma with small adrenal tumors). The COG experience with observation of apparent neuroblastoma without diagnostic biopsy is limited and under investigation.

Observation with biopsy (for infants aged <12 months with INRG stage MS disease without hepatomegaly and MYCN-nonamplified tumors; infants aged <12 months with localized disease, favorable histology and genomics, and MYCN-nonamplified tumors with no segmental chromosomal aberrations).

Chemotherapy with or without surgery (for symptomatic disease or unresectable progressive disease after surgery).

Sources: Chemotherapy with or without surgery

Radiation therapy (only for emergency therapy).

Health professional · Treatment of Non–High-Risk Neuroblastoma / Low-Risk Neuroblastoma / Treatment options for low-risk neuroblastoma

Surgery followed by observation

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Treatment for patients categorized as low risk may be surgery alone. For more information, see Table 3.

Sources: Table 3

Evidence (surgery followed by observation):

Results from the COG-P9641 (NCT00003119) study showed that surgery alone, even without complete resection, can cure nearly all patients with stage 1 neuroblastoma and the vast majority of patients with asymptomatic, favorable-biology, and International Neuroblastoma Staging System (INSS) stage 2A or stage 2B disease.[3]

Sources: COG-P9641 (NCT00003119) · 3

Similar outcomes were seen in a nonrandomized clinical trial in Japan.[6]

Sources: 6

Health professional · Treatment of Non–High-Risk Neuroblastoma / Low-Risk Neuroblastoma / Treatment options for low-risk neuroblastoma

Observation with or without biopsy

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Observation without biopsy has been used to treat perinatal neuroblastoma with small adrenal tumors.

A COG study determined that selected small INSS stage 1 or stage 2 adrenal masses, presumed to be neuroblastoma, detected in infants younger than 6 months by screening or incidental ultrasonography, may safely be observed without obtaining a definitive histological diagnosis and without surgical intervention. This technique avoids potential complications of surgery in newborn patients.[4] Patients are observed frequently to detect any tumor growth or spread, indicating a need for intervention. Additional studies, including an expansion of criteria allowing observation without surgery, are under way in the COG ANBL1232 (NCT02176967) study (closed to accrual).

Sources: 4 · ANBL1232 (NCT02176967)

Evidence (observation without biopsy):

The COG-ANBL00P2 (NCT00445718) study reported that expectant observation is safe in patients younger than 6 months with solid adrenal tumors smaller than 3.1 cm (or cystic tumors smaller than 5 cm) and INSS stage 1 disease.[4]

Sources: COG-ANBL00P2 (NCT00445718) · 4

The COG-ANBL00P2 (NCT00445718) study reported that expectant observation is safe in patients younger than 6 months with solid adrenal tumors smaller than 3.1 cm (or cystic tumors smaller than 5 cm) and INSS stage 1 disease.[4]

Sixty-seven of 83 patients (81%) demonstrated spontaneous regression and avoided surgical intervention.

Eighty-three of 87 eligible patients were observed without biopsy or resection; only 16 patients (19%) ultimately underwent surgery.

The 3-year EFS rate for a neuroblastoma event was 97.7%, and the OS rate was 100%.

Controversy exists about the need to attempt resection, at the time of diagnosis or later, in asymptomatic infants aged 12 months or younger with apparent stage 2B and stage 3 MYCN-nonamplified and favorable-biology disease. In a German clinical trial, some of these patients were observed after biopsy or partial resection without chemotherapy or radiation therapy. Many patients did not progress locally and never underwent a first or additional resection.[5] In the COG ANBL1232 (NCT02176967) study (closed to accrual), infants younger than 18 months who have L2 tumors with favorable biology are being observed after tumor biopsy.

Sources: 5 · ANBL1232 (NCT02176967)

Health professional · Treatment of Non–High-Risk Neuroblastoma / Low-Risk Neuroblastoma / Treatment options for low-risk neuroblastoma

Chemotherapy with or without surgery

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Chemotherapy with or without surgery is used to treat the following:

Symptomatic disease. The chemotherapy regimen consists of carboplatin, cyclophosphamide, doxorubicin, and etoposide. The cumulative chemotherapy dose of each agent is kept low to minimize long-term effects.[3]

Sources: 3

Unresectable progressive disease after surgery.

Evidence (for removal of chemotherapy):

The COG-P9641 study was one of the first COG studies to test risk stratification based on consensus-derived factors. In this phase III nonrandomized trial, 915 infants and children with INSS stage 2A and 2B disease underwent an initial operation to obtain tissue for diagnosis and biology studies and for maximal safe primary tumor resection. Chemotherapy was reserved for patients with, or at risk of, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone.[3]

Sources: COG-P9641 · 3

The COG-P9641 study was one of the first COG studies to test risk stratification based on consensus-derived factors. In this phase III nonrandomized trial, 915 infants and children with INSS stage 2A and 2B disease underwent an initial operation to obtain tissue for diagnosis and biology studies and for maximal safe primary tumor resection. Chemotherapy was reserved for patients with, or at risk of, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone.[3]

Stage 1:

The COG-P9641 study was one of the first COG studies to test risk stratification based on consensus-derived factors. In this phase III nonrandomized trial, 915 infants and children with INSS stage 2A and 2B disease underwent an initial operation to obtain tissue for diagnosis and biology studies and for maximal safe primary tumor resection. Chemotherapy was reserved for patients with, or at risk of, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone.[3] › Stage 1:

Patients with stage 1 disease achieved a 5-year EFS rate of 93% and a 5-year OS rate of 99%.

The COG-P9641 study was one of the first COG studies to test risk stratification based on consensus-derived factors. In this phase III nonrandomized trial, 915 infants and children with INSS stage 2A and 2B disease underwent an initial operation to obtain tissue for diagnosis and biology studies and for maximal safe primary tumor resection. Chemotherapy was reserved for patients with, or at risk of, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone.[3]

Stage 2A and 2B:

The COG-P9641 study was one of the first COG studies to test risk stratification based on consensus-derived factors. In this phase III nonrandomized trial, 915 infants and children with INSS stage 2A and 2B disease underwent an initial operation to obtain tissue for diagnosis and biology studies and for maximal safe primary tumor resection. Chemotherapy was reserved for patients with, or at risk of, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone.[3] › Stage 2A and 2B:

Asymptomatic patients with stage 2A and 2B disease (n = 306) who were observed after initial operation had a 5-year EFS rate of 87% and an OS rate of 96%.

The EFS rate was significantly better for patients with stage 2A than for patients with stage 2B neuroblastoma (92% vs. 85%; P = .0321), but OS did not differ significantly (98% vs. 96%; P = .2867).

The primary study objective (to achieve a 3-year OS rate of 95% for asymptomatic patients with stage 2A and 2B disease) was met.

Patients with stage 2B disease had a lower EFS and OS if they had an unfavorable histology (EFS rate, 72%; OS rate, 86%) or diploid tumors (EFS rate, 75%; OS rate, 84%) or were older than 18 months.

Outcomes for patients with stage 2B, diploid tumors, and unfavorable histology were particularly poor (EFS rate, 54%; OS rate, 70%), with no survivors among the few patients who had additional 1p loss of heterozygosity.

All the deaths occurred in children older than 18 months.

The COG-P9641 study was one of the first COG studies to test risk stratification based on consensus-derived factors. In this phase III nonrandomized trial, 915 infants and children with INSS stage 2A and 2B disease underwent an initial operation to obtain tissue for diagnosis and biology studies and for maximal safe primary tumor resection. Chemotherapy was reserved for patients with, or at risk of, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone.[3]

Outcome of asymptomatic patients at diagnosis who were observed after initial operation and patients treated with chemotherapy postoperatively: Of the initial 915 patients, 800 were asymptomatic at diagnosis and observed after their initial operations. Within this group, 11% of patients experienced recurrent or progressive disease. Of the 115 patients who underwent surgery followed by immediate chemotherapy (median, 4 cycles; range, 1–8 cycles), 81% of the patients had a very good partial response or better. After chemotherapy, 10% of the patients had disease recurrence or progression.

The COG-P9641 study was one of the first COG studies to test risk stratification based on consensus-derived factors. In this phase III nonrandomized trial, 915 infants and children with INSS stage 2A and 2B disease underwent an initial operation to obtain tissue for diagnosis and biology studies and for maximal safe primary tumor resection. Chemotherapy was reserved for patients with, or at risk of, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone.[3] › Outcome of asymptomatic patients at diagnosis who were observed after initial operation and patients treated with chemotherapy postoperatively: Of the initial 915 patients, 800 were asymptomatic at diagnosis and observed after their initial operations. Within this group, 11% of patients experienced recurrent or progressive disease. Of the 115 patients who underwent surgery followed by immediate chemotherapy (median, 4 cycles; range, 1–8 cycles), 81% of the patients had a very good partial response or better. After chemotherapy, 10% of the patients had disease recurrence or progression.

For patients treated with surgery alone, the 5-year EFS rate was 89%, and the OS estimate was 97%.

For patients treated with surgery and immediate chemotherapy, the 5-year EFS rate was 91%, and the OS estimate was 98%.

The COG-P9641 study was one of the first COG studies to test risk stratification based on consensus-derived factors. In this phase III nonrandomized trial, 915 infants and children with INSS stage 2A and 2B disease underwent an initial operation to obtain tissue for diagnosis and biology studies and for maximal safe primary tumor resection. Chemotherapy was reserved for patients with, or at risk of, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone.[3]

MYCN amplification: The impact of MYCN-amplified tumors was analyzed in patients with stage 1 disease.

The COG-P9641 study was one of the first COG studies to test risk stratification based on consensus-derived factors. In this phase III nonrandomized trial, 915 infants and children with INSS stage 2A and 2B disease underwent an initial operation to obtain tissue for diagnosis and biology studies and for maximal safe primary tumor resection. Chemotherapy was reserved for patients with, or at risk of, symptomatic disease, with less than 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone.[3] › MYCN amplification: The impact of MYCN-amplified tumors was analyzed in patients with stage 1 disease.

For patients with MYCN-nonamplified tumors, the 5-year EFS rate was 93%, and the OS rate was 99%.

For patients with MYCN-amplified tumors, the 5-year EFS rate was 70% (P = .0042), and the OS rate was 80% (P < .001).

Health professional · Treatment of Non–High-Risk Neuroblastoma / Low-Risk Neuroblastoma

Treatment options under clinical evaluation

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional · Treatment of Non–High-Risk Neuroblastoma

Intermediate-Risk Neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

According to the 2021 COG risk classifier, intermediate risk includes the following for localized, INRG stage L2 tumors (no MYCN amplification):[1]

Sources: 1

Children younger than 5 years with favorable biology.

Children older than 5 years with favorable biology and differentiating tumors (International Neuroblastoma Pathology Classification [INPC]).

Children younger than 365 days with unfavorable histology (UH), DNA Index (DI) higher than 1, no segmental chromosomal alterations (SCAs).

Children younger than 365 days with FH, DI is 1, no SCAs.

Children younger than 365 days with UH, DI is 1, no SCAs.

Children younger than 365 days with FH, DI higher than 1, and SCAs.

Children older than 365 days with FH and SCAs.

Children younger than 365 days with SCAs (with either UH or DI = 1).

Children aged 365 days to younger than 547 days with UH.

Stage M (no MYCN amplification):[1]

Sources: 1

Children younger than 365 days with all favorable biology.

Children younger than 365 days with 1 or more unfavorable biological features.

Children aged 365 days to younger than 547 days with FH, DI higher than 1, no SCAs.

Stage MS (no MYCN amplification):[1]

Sources: 1

Children younger than 3 months with evolving hepatomegaly or symptomatic with all favorable biology.

Symptomatic children with unfavorable biology.

Children aged 365 days to younger than 18 months, FH, and no SCAs (DI > 1).

For infants with stage MS tumors who are too unstable to undergo biopsy before starting treatment, chemotherapy is initiated, and a biopsy is obtained when safe.

For more information about the COG risk categories, see Table 3.

Sources: Table 3

For more information about stage 4S and MS tumors, see the Treatment of INSS Stage 4S and INRG Stage MS Neuroblastoma section.

Sources: Treatment of INSS Stage 4S and INRG Stage MS Neuroblastoma

Health professional · Treatment of Non–High-Risk Neuroblastoma / Intermediate-Risk Neuroblastoma

Treatment options for intermediate-risk neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Treatment options for intermediate-risk neuroblastoma include the following:

Chemotherapy with or without surgery.

Sources: Chemotherapy with or without surgery

Surgery and observation (in infants).

Sources: Surgery and observation

Radiation therapy (for progressive disease, if needed).

Sources: Radiation therapy

Health professional · Treatment of Non–High-Risk Neuroblastoma / Intermediate-Risk Neuroblastoma / Treatment options for intermediate-risk neuroblastoma

Chemotherapy with or without surgery

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Patients categorized as intermediate risk have been successfully treated with complete surgical resection and two, four, or eight cycles of neoadjuvant chemotherapy. The chemotherapy regimen consists of carboplatin, cyclophosphamide, doxorubicin, and etoposide. The cumulative dose of each agent is kept low to minimize long-term effects from the chemotherapy regimen (ANBL0531 [NCT00499616]). As a rule, patients whose tumors had unfavorable biology received eight cycles of chemotherapy, and patients whose tumors had favorable biology received either two or four cycles of chemotherapy. Favorable biological features include FH, DI higher than 1, and no SCAs.

Sources: ANBL0531 [NCT00499616]

Tumor response assessment is measured with a single dimension, as per Response Evaluation Criteria in Solid Tumors (RECIST). After the number of assigned cycles of chemotherapy (based on disease stage, age, and biological features), if greater than a partial response has not been obtained, then a multidisciplinary discussion should occur to discuss the role of surgery versus additional chemotherapy. Patients who achieve a partial response or greater will enter surveillance. Surgical resection should be considered if chemotherapy has resulted in less than 50% reduction in tumor size. For patients unable to undergo surgical resection, and additional chemotherapy is given, response should be re-evaluated after every two cycles of therapy. Another biopsy to look for histological differentiation may be necessary to assess a residual mass that did not shrink sufficiently with chemotherapy.[7]

Sources: 7

In cases of abdominal neuroblastoma thought to involve a kidney, nephrectomy is not undertaken before a course of chemotherapy has been given.[8] Nephrectomy should be avoided in all cases.

Sources: 8

Cyclophosphamide and topotecan were used in the ANBL0531 (NCT00499616) study as additional treatment in patients who had received eight cycles of intermediate-risk chemotherapy and did not achieve the targeted response.[9,10]

Sources: ANBL0531 (NCT00499616) · 9 · 10

Whether initial chemotherapy is indicated for all intermediate-risk infants with localized neuroblastoma requires further study.

Evidence (chemotherapy with or without surgery):

The goal of the ANBL0531 (NCT00499616) study was to reduce therapy for subsets of patients with intermediate-risk neuroblastoma (MYCN-nonamplified, age and stage defined). Treatment duration (two, four, or eight cycles of moderate-dose neoadjuvant chemotherapy) was assigned according to clinical features and a tumor biology (including allelic status of 1p36 and 11q23) and response-based algorithm. The 10-year EFS and OS rates for the entire study cohort (N = 404) were 82.0% and 94.7%, respectively.[10] Treatment duration and intensity was reduced for several subsets of patients. The study added stage 4 patients with favorable biology who were aged 12 to 18 months.[9]

Sources: ANBL0531 (NCT00499616) · 10 · 9

The goal of the ANBL0531 (NCT00499616) study was to reduce therapy for subsets of patients with intermediate-risk neuroblastoma (MYCN-nonamplified, age and stage defined). Treatment duration (two, four, or eight cycles of moderate-dose neoadjuvant chemotherapy) was assigned according to clinical features and a tumor biology (including allelic status of 1p36 and 11q23) and response-based algorithm. The 10-year EFS and OS rates for the entire study cohort (N = 404) were 82.0% and 94.7%, respectively.[10] Treatment duration and intensity was reduced for several subsets of patients. The study added stage 4 patients with favorable biology who were aged 12 to 18 months.[9]

In the legacy (A3961 [NCT00003093]) study, the administration of neoadjuvant chemotherapy facilitated at least a partial resection of 99.6% of previously unresectable tumors. No significant difference was noted in OS according to the degree of resection accomplished (complete vs. incomplete) in either study.[9,11]

Sources: A3961 [NCT00003093] · 9 · 11

Less than 3% of patients in the ANBL0531 study received local radiation therapy, and only the patients with progressive hepatic enlargement or spinal cord compression received radiation therapy.[9]

Sources: 9

Inferior EFS, but not OS, was observed among patients who had tumors with 11q loss of heterozygosity (n = 26) compared with those who had tumors without 11q loss of heterozygosity (n = 314) (10-year EFS rates, 68.4% vs. 83.9%; P = .03; 10-year OS rates, 88.0% vs. 95.7%; P = .09).[10]

Sources: 10

The 3-year EFS rate was 92% for patients with stage 3 disease with favorable histopathology (n = 269); 90% for patients with stage 4S disease and unfavorable biology, including diploidy or unfavorable histology (n = 31); and 81% for infants with stage 4 disease (n = 176) (P < .001 for stages 3 and 4S vs. stage 4).

Infants with stage 4 disease with favorable biology (n = 61) had a superior 10-year EFS, compared with those with confirmed unfavorable biology tumors (n = 47) (10-year EFS rate, 86.9% vs. 66.8%; P = .02), although OS was not significantly different (10-year OS rate, 95.0% vs. 84.4%; P = .08).[10]

Sources: 10

Only infants were stratified by ploidy. Those with diploid tumors received eight versus four cycles of chemotherapy. The 3-year OS rate estimates were 98% for stage 3 disease, 97% for stage 4S disease, and 93% for stage 4 disease (P = .002 for stages 3 and 4S vs. stage 4). Infants with diploidy had a poorer outcome (P = .03), as did all patients with diploidy studied, when combined (P = .03).

In patients with favorable biological features, there was no difference in OS between those who received eight cycles of chemotherapy (100%) for persistent disease and those who received four cycles (96%).

There was no unexpected toxicity.

Patients who had not achieved a PR (n = 27) (after completing therapy with eight cycles of carboplatin, cyclophosphamide, doxorubicin, and etoposide) were then treated with cyclophosphamide and topotecan to reach a PR. These patients had an inferior EFS than those who did not require cyclophosphamide and topotecan to reach a PR.

During long-term follow-up beyond 3 years, there were only three patients who experienced disease relapse, suggesting that ongoing surveillance beyond that time point may not be useful.[10]

Sources: 10

A German prospective clinical trial enrolled 340 infants aged 1 year or younger whose tumors were stage 1, 2, or 3; histologically verified; and lacked MYCN amplification. Chemotherapy was given at diagnosis to 57 infants with organs threatened by the tumor. The tumor was completely resected or nearly so in 190 infants who underwent low-risk surgery. A total of 93 infants whose tumors were not resectable without high-risk surgery because of age or organ involvement were observed without chemotherapy.[5]

Sources: 5

A German prospective clinical trial enrolled 340 infants aged 1 year or younger whose tumors were stage 1, 2, or 3; histologically verified; and lacked MYCN amplification. Chemotherapy was given at diagnosis to 57 infants with organs threatened by the tumor. The tumor was completely resected or nearly so in 190 infants who underwent low-risk surgery. A total of 93 infants whose tumors were not resectable without high-risk surgery because of age or organ involvement were observed without chemotherapy.[5]

The 3-year OS rate was excellent (95%) for infants who received chemotherapy.

Further surgery was avoided in 33 infants, and chemotherapy was avoided in 72 infants.

The 3-year OS rate for the infants who were observed without treatment was 99%. The metastases-free survival rate was 94% for infants with unresected tumors and did not differ from the rate for infants treated with surgery or chemotherapy (median follow-up, 58 months).

Forty-four of 93 infants with unresected tumors experienced spontaneous regression (17 were complete regressions), and 39 infants experienced progression.

The investigators suggested that a wait-and-see strategy is appropriate for infants with localized neuroblastoma because regressions have been observed after the first year of life.

Moderate-dose chemotherapy has been shown to be effective in the prospective Infant Neuroblastoma European Study (EURO-INF-NB-STUDY-1999-99.1). About one-half of the infants with unresectable, nonmetastatic neuroblastoma and no MYCN amplification underwent a safe surgical resection and avoided long-term adverse effects.[12][Level of evidence C1]

Sources: EURO-INF-NB-STUDY-1999-99.1 · 12 · Level of evidence C1

Moderate-dose chemotherapy has been shown to be effective in the prospective Infant Neuroblastoma European Study (EURO-INF-NB-STUDY-1999-99.1). About one-half of the infants with unresectable, nonmetastatic neuroblastoma and no MYCN amplification underwent a safe surgical resection and avoided long-term adverse effects.[12][Level of evidence C1]

The 5-year OS rate was 99%, and the EFS rate was 90% (median follow-up, 6 years).

In this study, infants who underwent surgical resection had a better EFS than did those who did not have surgery.

In two European prospective trials of infants with disseminated neuroblastoma without MYCN gene amplification, infants with INSS stage 3 primary or positive skeletal scintigraphy without radiological bone metastasis (identified mostly by MIBG scan, but a few with just technetium Tc 99m bone scan) were not administered chemotherapy unless life-threatening or organ-threatening symptoms developed. When given, chemotherapy consisted of short and standard doses.[13]

Sources: 13

In two European prospective trials of infants with disseminated neuroblastoma without MYCN gene amplification, infants with INSS stage 3 primary or positive skeletal scintigraphy without radiological bone metastasis (identified mostly by MIBG scan, but a few with just technetium Tc 99m bone scan) were not administered chemotherapy unless life-threatening or organ-threatening symptoms developed. When given, chemotherapy consisted of short and standard doses.[13]

The OS rate was 100% in the 41 patients who did not have INSS stage 4S, regardless of initial chemotherapy.

In infants with overt metastases to the skeleton, lung, and central nervous system (by radionuclide scan, but not by plain x-ray or computed tomography [CT] scan), the 2-year OS rate was 96% (n = 45).

No patients died of surgery-related or chemotherapy-related complications on either protocol.

A retrospective analysis from the COG evaluated patients aged 12 to 18 months with metastatic disease and favorable biological features. In legacy trials, these patients were treated with high-risk disease regimens.[14]

Sources: 14

A retrospective analysis from the COG evaluated patients aged 12 to 18 months with metastatic disease and favorable biological features. In legacy trials, these patients were treated with high-risk disease regimens.[14]

This analysis demonstrated that this group of patients had similar excellent outcomes with intermediate-risk therapy, compared with high-risk therapy. These patients are now treated with intermediate-risk therapy in current clinical trials.

A prospective International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) trial treated infants with MYCN-nonamplified, stage 2 or stage 3 unresectable neuroblastoma, as well as those aged 12 to 18 months who had favorable INPC.[15][Level of evidence C2]

Sources: 15 · Level of evidence C2

A prospective International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) trial treated infants with MYCN-nonamplified, stage 2 or stage 3 unresectable neuroblastoma, as well as those aged 12 to 18 months who had favorable INPC.[15][Level of evidence C2]

The EFS rate was 98% with conventional chemotherapy.

These results are similar to results from the COG-A3961 trial.

Health professional · Treatment of Non–High-Risk Neuroblastoma / Intermediate-Risk Neuroblastoma / Treatment options for intermediate-risk neuroblastoma

Surgery and observation (in infants)

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

The need for chemotherapy in all asymptomatic infants with stage 3 or stage 4 disease is controversial, as some European studies have shown favorable outcomes with surgery and observation.[13]

Sources: 13

Evidence (surgery and observation in infants):

A French study classified infants as stage 4 because of a primary tumor infiltrating across the midline (INSS stage 3 primary with metastases limited to 4S category) or positive bone scintigraphy not associated with changes in the cortical bone documented on plain radiographs and/or CT.[16]

Sources: 16

A French study classified infants as stage 4 because of a primary tumor infiltrating across the midline (INSS stage 3 primary with metastases limited to 4S category) or positive bone scintigraphy not associated with changes in the cortical bone documented on plain radiographs and/or CT.[16]

Infants with this classification were reported to have a better outcome with less aggressive chemotherapy than were other stage 4 infants (EFS rate, 90% vs. 27%).

However, a much higher proportion of those with radiologically demonstrated cortical bone lesions also had tumors with MYCN amplification.

Building on the French study, SIOPEN conducted a prospective trial of 125 infants (n = 41 with INSS 3 primary tumors or positive scintigraphy) with disseminated neuroblastoma without MYCN amplification to determine whether these patients could be observed in the absence of symptoms. However, treating physicians did not always follow the wait-and-see strategy.[13]

Sources: 13

Building on the French study, SIOPEN conducted a prospective trial of 125 infants (n = 41 with INSS 3 primary tumors or positive scintigraphy) with disseminated neuroblastoma without MYCN amplification to determine whether these patients could be observed in the absence of symptoms. However, treating physicians did not always follow the wait-and-see strategy.[13]

There was no significant difference in 2-year OS rates between patients with unresectable primary tumors and patients with resectable primary tumors (97% vs. 100%) and between patients with negative and positive skeletal scintigraphy without radiological abnormalities (100% vs. 97%).

A German prospective clinical trial enrolled 340 infants aged 1 year or younger whose tumors were stage 1, 2, or 3; verified histologically; and lacked MYCN amplification. Of the 190 infants who underwent resection, 8 had stage 3 disease. A total of 93 infants whose tumors were not resectable without high-risk surgery, because of age or organ involvement, were observed without chemotherapy, which included 21 patients with stage 3 disease. Fifty-seven infants, including 41 with stage 3 disease, were treated with chemotherapy to control threatening symptoms.[5]

Sources: 5

A German prospective clinical trial enrolled 340 infants aged 1 year or younger whose tumors were stage 1, 2, or 3; verified histologically; and lacked MYCN amplification. Of the 190 infants who underwent resection, 8 had stage 3 disease. A total of 93 infants whose tumors were not resectable without high-risk surgery, because of age or organ involvement, were observed without chemotherapy, which included 21 patients with stage 3 disease. Fifty-seven infants, including 41 with stage 3 disease, were treated with chemotherapy to control threatening symptoms.[5]

The 3-year OS rate was excellent for the entire group of infants with unresected tumors (99%), infants who received chemotherapy (95%), and infants with resected tumors (98%) (P = .45).

Health professional · Treatment of Non–High-Risk Neuroblastoma / Intermediate-Risk Neuroblastoma / Treatment options for intermediate-risk neuroblastoma

Radiation therapy

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Radiation therapy for children with intermediate-risk disease is reserved for patients with progressive disease during treatment with chemotherapy or progressive unresectable disease after treatment with chemotherapy.

In a prospective randomized COG trial that tested reduced-intensity chemotherapy for patients with intermediate-risk neuroblastoma, only 12 of 479 patients (2.5%) received local radiation therapy (21 Gy). One patient had stage 4S disease, five patients had stage 3 disease, and six patients had stage 4 disease. Radiation therapy was administered for clinical deterioration despite initial therapy (eight patients), residual macroscopic disease and unfavorable biological features (three patients), or relapse after therapy (one patient).[2,11,17]

Sources: 2 · 11 · 17

Health professional · Treatment of Non–High-Risk Neuroblastoma / Intermediate-Risk Neuroblastoma

Treatment options under clinical evaluation

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional

Treatment of High-Risk Neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Patients most at risk for disease progression and mortality are older than 18 months, have metastatic disease or localized disease with unfavorable biology such as MYCN amplification, or have unfavorable histology. For more information about the Children's Oncology Group (COG) risk categories, see Table 3.

Sources: Table 3

Approximately 8% to 10% of infants with stage MS disease have MYCN-amplified tumors and are usually treated using high-risk protocols. The 5-year event-free survival (EFS) and overall survival (OS) rates were 60% and 64%, respectively, for the infants with stage MS disease and MYCN amplification (n = 23), among the 5,000 patients enrolled in the COG ANBL00B1 (NCT00904241) trial.[1]

Sources: ANBL00B1 (NCT00904241) · 1

For children with high-risk neuroblastoma who received current treatments, the 5-year OS rate was about 60% for patients diagnosed between 2007 and 2017.[1] Children with aggressively treated, high-risk neuroblastoma may develop late recurrences, some more than 5 years after completion of therapy.[2,3]

Sources: 1 · 2 · 3

A study from the International Neuroblastoma Risk Group (INRG) database found 146 patients with distant metastases limited to lymph nodes, termed stage 4N, who tended to have favorable-biology disease and a good outcome (5-year OS rate, 85%). This finding suggests that for this very rare, special subgroup of high-risk, stage 4 patients, less-intensive therapy might be considered.[4] These more favorable outcomes were confirmed in a single-institution study of 51 patients.[5]

Sources: 4 · 5

Health professional · Treatment of High-Risk Neuroblastoma

Treatment Options for High-Risk Neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Outcomes for patients with high-risk neuroblastoma remain poor despite recent improvements in survival in randomized trials.

Treatment options for high-risk neuroblastoma typically include the following:

A regimen of chemotherapy, surgery, tandem cycles of myeloablative therapy and hematopoietic stem cell transplant (HSCT), radiation therapy, and dinutuximab, with granulocyte-macrophage colony-stimulating factor (GM-CSF) and isotretinoin.

Sources: A regimen of chemotherapy, surgery, tandem cycles of myeloablative therapy and hematopoietic stem cell transplant (HSCT), radiation therapy, and dinutuximab, with granulocyte-macrophage colony-stimulating factor (GM-CSF) and isotretinoin

Health professional · Treatment of High-Risk Neuroblastoma / Treatment Options for High-Risk Neuroblastoma

Chemotherapy, surgery, tandem cycles of myeloablative therapy and HSCT, radiation therapy, and dinutuximab, with GM-CSF and isotretinoin

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Treatment for patients with high-risk disease is generally divided into the following three phases:

Induction (includes chemotherapy and surgical resection).

Sources: Induction

Consolidation (tandem cycles of myeloablative therapy and HSCT and radiation therapy to the site of the primary tumor and residual metastatic sites).

Sources: Consolidation

Postconsolidation (immunotherapy with GM-CSF and isotretinoin therapy).

Sources: Postconsolidation

Health professional · Treatment of High-Risk Neuroblastoma / Treatment Options for High-Risk Neuroblastoma / Chemotherapy, surgery, tandem cycles of myeloablative therapy and HSCT, radiation therapy, and dinutuximab, with GM-CSF and isotretinoin

Induction phase

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

The backbone of the most commonly used induction therapy includes dose-intensive cycles of cisplatin and etoposide alternating with vincristine, cyclophosphamide, and doxorubicin.[6] Topotecan and cyclophosphamide were added to this regimen based on the antineuroblastoma activity seen in patients with relapsed disease.[7] Response to therapy after four cycles of chemotherapy or at the end of induction chemotherapy correlates with EFS at the completion of high-risk therapy.[8-10]

Sources: 6 · 7 · 8 · 10

Evidence (induction chemotherapy with or without additional treatments):

In one study, the addition of anti-GD2 antibody therapy with GM-CSF and low-dose interleukin-2 (IL-2), given with each induction chemotherapy course, had encouraging outcomes in 42 children with newly diagnosed stage 4 disease.[11]

Sources: 11

In one study, the addition of anti-GD2 antibody therapy with GM-CSF and low-dose interleukin-2 (IL-2), given with each induction chemotherapy course, had encouraging outcomes in 42 children with newly diagnosed stage 4 disease.[11]

This induction therapy, followed by standard consolidation and postconsolidation therapy, produced early partial responses or better in most patients, reduced tumor volumes, and an encouraging 3-year EFS rate of 73.7%.

A European prospective randomized controlled trial investigated extended induction therapy in 422 patients with newly diagnosed high-risk neuroblastoma. Patients were randomly assigned to receive either standard induction chemotherapy with six chemotherapy courses or experimental induction chemotherapy that began with two additional courses of topotecan, cyclophosphamide, and etoposide, followed by standard induction chemotherapy.[12][Level of evidence B3]

Sources: 12 · Level of evidence B3

A European prospective randomized controlled trial investigated extended induction therapy in 422 patients with newly diagnosed high-risk neuroblastoma. Patients were randomly assigned to receive either standard induction chemotherapy with six chemotherapy courses or experimental induction chemotherapy that began with two additional courses of topotecan, cyclophosphamide, and etoposide, followed by standard induction chemotherapy.[12][Level of evidence B3]

The 3-year EFS rate was 34% for patients who received the experimental induction regimen and 32% for patients who received the standard induction regimen.

The addition of two topotecan-containing chemotherapy courses did not improve the EFS of patients with high-risk neuroblastoma and resulted in more toxicity per patient.

European investigators completed another randomized study of induction regimens for patients with high-risk neuroblastoma. A total of 630 patients were randomly assigned to receive either cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide (rCOJEC regimen; n = 313) or the Memorial Sloan Kettering Cancer Center N5 induction regimens (MSKCC-N5; n = 317).[13][Level of evidence B1]

Sources: 13 · Level of evidence B1

European investigators completed another randomized study of induction regimens for patients with high-risk neuroblastoma. A total of 630 patients were randomly assigned to receive either cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide (rCOJEC regimen; n = 313) or the Memorial Sloan Kettering Cancer Center N5 induction regimens (MSKCC-N5; n = 317).[13][Level of evidence B1]

There were no significant differences in metastatic complete response rates between the two regimens (32% for rCOJEC vs. 35% for MSKCC-N5; P = .368) or 3-year EFS rates (44% for rCOJEC vs. 47% for MSKCC-N5; P = .527).

Patients who received the rCOJEC regimen experienced less acute toxicity.

The rCOJEC regimen has been selected as the standard induction regimen for the current International Society of Pediatric Oncology European Neuroblastoma (SIOPEN) trial.

After a response to induction chemotherapy, resection of the primary tumor is recommended by most treatment protocols. Whether a gross-total resection is beneficial is controversial.[14]

Sources: 14

Evidence (extent of resection of the primary tumor):

The COG A3973 (NCT00004188) study had central surgical review of 220 patients who underwent attempted gross-total resection after induction chemotherapy. By the surgeon’s estimate, the degree of resection was determined to be 90% or greater versus less than 90%, but only 63% concordance with central review of imaging was found.[15][Level of evidence C1]

Sources: A3973 (NCT00004188) · 15 · Level of evidence C1

The COG A3973 (NCT00004188) study had central surgical review of 220 patients who underwent attempted gross-total resection after induction chemotherapy. By the surgeon’s estimate, the degree of resection was determined to be 90% or greater versus less than 90%, but only 63% concordance with central review of imaging was found.[15][Level of evidence C1]

Nevertheless, the surgeon’s assessment of 90% or greater resection versus less than 90% resection predicted an EFS rate of 46% versus 38% (P = .01), respectively, and a cumulative incidence of local relapse rate of 8.5% versus 20%, respectively.

OS rates were not significantly different between the two groups (57% vs. 49%, P = .3).

The authors' conclusion supports continued efforts to achieve greater than 90% resection to decrease local recurrence.

A single-center retrospective study of 87 children with high-risk neuroblastoma demonstrated no significant benefit of gross-total resection compared with near-total (>90%) resection.[16][Level of evidence C2]

Sources: 16 · Level of evidence C2

A single-center retrospective study of 87 children with high-risk neuroblastoma demonstrated no significant benefit of gross-total resection compared with near-total (>90%) resection.[16][Level of evidence C2]

However, the results suggest that greater than 90% resection is associated with improved OS compared with less than 90% resection.

The potential benefit of aggressive surgical approaches in high-risk patients with metastatic disease to achieve complete tumor resection, either at the time of diagnosis or after chemotherapy, has not been unequivocally demonstrated. Several studies have reported that complete resection of the primary tumor at diagnosis improved survival. However, the outcome in these patients may be more dependent on the biology of the tumor, which itself may determine resectability, than on the extent of surgical resection.[17-19]

Sources: 17 · 19

In patients older than 18 months with stage 4 neuroblastoma, controversy exists about whether there is any advantage to gross-total resection of the primary tumor after chemotherapy.[15,18-20] In some studies, patients who underwent incomplete resections fared less well than those who underwent complete resections.[21] These outcomes could have resulted from either the biology of unresectable tumors or reduction of tumor bulk.[22][Level of evidence B1] Complete resection that requires nephrectomy is not recommended because of the nephrotoxic nature of standard chemotherapy and unproven effect of complete resection on outcome.

Sources: 15 · 18 · 20 · 21 · 22 · Level of evidence B1

In most group studies, surgical resection of the primary tumor is performed during the induction phase. However, the JN-H-11 trial evaluated the feasibility of delayed resection after high-dose chemotherapy with stem cell rescue, with the goal of prioritizing systemic therapy.[23] Rates of complete or greater-than-90% resection were similar to those seen in a previous trial, in which surgery was performed during induction. The rate of nephrectomy was nominally lower (5.8% vs. 17%), and the 3-year cumulative incidence of local failure rate was nominally higher (17.3% vs. 11.6%), compared with the rates found in the previous trial.

Sources: 23

At the end of induction therapy, patients with high-risk disease typically undergo a full disease evaluation. Management of patients with residual disease at the end of conventional induction therapy is not standardized. A retrospective study analyzed 201 patients with high-risk disease who had a partial response or less at the end of induction therapy. Patients were selected to immediately receive either high-dose chemotherapy (cohort 1), bridging therapy (usually chemoimmunotherapy or iodine I 131-metaiodobenzylguanidine [MIBG]) followed by high-dose chemotherapy (cohort 2), or additional therapy but not high-dose chemotherapy (cohort 3).[24]

Sources: 24

Despite having less-favorable features, patients in cohort 2 had similar EFS compared with patients in cohort 1, while patients in cohort 3 had inferior EFS.

Among patients with stable disease in metastatic sites at the end of induction therapy, patients in cohort 2 had superior EFS compared with patients in cohort 1.

These retrospective data suggest a role for bridging therapy in patients with incomplete response to conventional induction therapy.

Health professional · Treatment of High-Risk Neuroblastoma / Treatment Options for High-Risk Neuroblastoma / Chemotherapy, surgery, tandem cycles of myeloablative therapy and HSCT, radiation therapy, and dinutuximab, with GM-CSF and isotretinoin

Consolidation phase

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

The consolidation phase of high-risk regimens involves myeloablative chemotherapy and HSCT, which attempts to eradicate minimal residual disease (MRD) using otherwise lethal doses of ablative chemotherapy rescued by autologous stem cells (collected during induction chemotherapy) to repopulate the bone marrow. Several large randomized controlled studies showed improved 3-year EFS rates for treatment with HSCT (31%–47%) versus conventional chemotherapy (22%–31%).[25-27] Previously, total-body irradiation had been used in HSCT conditioning regimens. Most current protocols in North America use tandem cycles of chemotherapy and HSCT with cyclophosphamide/thiotepa and carboplatin/etoposide/melphalan.[28][Level of evidence C1] In Europe, clinical trials have also evaluated busulfan/melphalan and HSCT.

Sources: 25 · 27 · 28 · Level of evidence C1

Evidence (myeloablative chemotherapy and stem cell rescue):

A large European multicenter trial of consolidation therapy randomly assigned patients who had completed a multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide with or without topotecan, vincristine, and doxorubicin) and achieved an adequate response to receive either busulfan/melphalan or carboplatin/etoposide/melphalan.[29][Level of evidence A1]

Sources: 29 · Level of evidence A1

A large European multicenter trial of consolidation therapy randomly assigned patients who had completed a multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide with or without topotecan, vincristine, and doxorubicin) and achieved an adequate response to receive either busulfan/melphalan or carboplatin/etoposide/melphalan.[29][Level of evidence A1]

Induction therapy with cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide, and consolidation for HSCT with busulfan/melphalan resulted in an improved EFS, without an effect on OS or severe adverse events.

A randomized clinical study (COG-ANBL0532) tested the efficacy of two cycles versus one cycle of myeloablative chemotherapy with stem cell rescue.[30][Level of evidence A1] Children older than 18 months with stage 4 neuroblastoma who had received six cycles of induction chemotherapy were then randomly assigned to receive a single autologous HSCT with carboplatin/etoposide/melphalan or tandem transplants with cyclophosphamide/thiotepa followed by reduced-dose carboplatin/etoposide/melphalan. After tumor bed radiation therapy, most patients were randomly assigned to a second separate trial to receive isotretinoin alone or isotretinoin with dinutuximab and immune enhancement.

Sources: COG-ANBL0532 · 30 · Level of evidence A1

A randomized clinical study (COG-ANBL0532) tested the efficacy of two cycles versus one cycle of myeloablative chemotherapy with stem cell rescue.[30][Level of evidence A1] Children older than 18 months with stage 4 neuroblastoma who had received six cycles of induction chemotherapy were then randomly assigned to receive a single autologous HSCT with carboplatin/etoposide/melphalan or tandem transplants with cyclophosphamide/thiotepa followed by reduced-dose carboplatin/etoposide/melphalan. After tumor bed radiation therapy, most patients were randomly assigned to a second separate trial to receive isotretinoin alone or isotretinoin with dinutuximab and immune enhancement.

The 3-year EFS rate from the time of randomization was 62% for tandem transplants and 48% for single HSCT (P = .006). The 3-year OS rate was 74% for tandem autologous HSCTs and 69% for single autologous HSCT (P = .25).

For randomized patients who subsequently received dinutuximab and immune enhancement, the 3-year EFS rate was 73% for tandem HSCTs and 55% for single HSCT (P = .004), while the OS rate was 84% and 74%, respectively.[30][Level of evidence B1]

Sources: 30 · Level of evidence B1

These study results have an important limitation: a substantial portion of the patients were not randomly assigned to therapy (because of patient and provider preference), introducing a potential selection bias.

An updated Cochrane review evaluated three randomized clinical trials comparing autologous bone marrow transplant (BMT) with standard chemotherapy.[25-27,31,32]

Sources: 25 · 27 · 31 · 32

An updated Cochrane review evaluated three randomized clinical trials comparing autologous bone marrow transplant (BMT) with standard chemotherapy.[25-27,31,32]

EFS was significantly better for autologous BMT, but there was no statistically significant difference in OS.

A review of 147 allogeneic transplant cases submitted to the Center for International Blood and Marrow Transplant Research found no advantage for allogeneic transplant over autologous transplant, even if the allogeneic transplant recipient had received a previous autologous transplant.[33]

Sources: 33

In a separate prospective randomized study, there was no advantage to purging harvested autologous stem cells of neuroblastoma cells before transplant.[34]

Sources: 34

For more information about transplant, see Pediatric Autologous Hematopoietic Stem Cell Transplant and Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy for Cancer.

Sources: Pediatric Autologous Hematopoietic Stem Cell Transplant · Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy for Cancer

Radiation to the primary tumor site (whether or not a complete excision was obtained) is indicated after myeloablative therapy.[35,36]; [37][Level of evidence C1] Boost radiation therapy for gross-residual disease did not show improved local control when studied prospectively in the ANBL0532 (NCT00567567) trial.[38][Level of evidence C1] The optimal dose of radiation therapy has not been determined.[39]

Sources: 35 · 36 · 37 · Level of evidence C1 · ANBL0532 (NCT00567567) · 38 · Level of evidence C1 · 39

Evidence (radiation therapy with a boost vs. radiation therapy without a boost for incomplete resection):

Because of the high rates of local recurrence after incomplete surgical resection, the COG ANBL0532 (NCT00567567) trial prospectively evaluated the potential benefit of boost radiation therapy for patients with gross-residual tumor and compared the results with the preceding COG clinical trial for high-risk neuroblastoma (A3973 [NCT00004188]), in which patients did not receive boost radiation therapy. All patients on the ANBL0532 trial received 21.6 Gy of radiation to the preoperative primary tumor volume after induction chemotherapy.[38][Level of evidence C1]

Sources: ANBL0532 (NCT00567567) · A3973 [NCT00004188] · 38 · Level of evidence C1

Because of the high rates of local recurrence after incomplete surgical resection, the COG ANBL0532 (NCT00567567) trial prospectively evaluated the potential benefit of boost radiation therapy for patients with gross-residual tumor and compared the results with the preceding COG clinical trial for high-risk neuroblastoma (A3973 [NCT00004188]), in which patients did not receive boost radiation therapy. All patients on the ANBL0532 trial received 21.6 Gy of radiation to the preoperative primary tumor volume after induction chemotherapy.[38][Level of evidence C1]

There were no differences in outcomes between the patients in the ANBL0532 trial who received a single HSCT and boost radiation therapy (n = 74) and the patients in the A3973 trial who underwent an incomplete resection and received no boost radiation therapy (n = 47).

The 5-year cumulative incidence of local progression was 16.3% for patients in the ANBL0532 trial versus 10.6% for patients in the A3973 trial (P = .4126).

The EFS rate was 50.9% for patients in the ANBL0532 trial versus 48.9% for patients in the A3973 trial (P = .5084).

The OS rate was 68.1% for patients in the ANBL0532 trial versus 56.9% for patients in the A3973 trial (P = .2835).

Boost radiation therapy administered to gross residual tumor that was present at the end of induction did not significantly improve the 5-year cumulative incidence of local progression; therefore, it is not recommended.[38]

Sources: 38

Extensive lymph node irradiation, regardless of the extent of surgical resection preceding HSCT, did not benefit patients for local progression or OS.[40][Level of evidence C1]

Sources: 40 · Level of evidence C1

A detailed retrospective multicenter review of locoregional recurrences demonstrated that 48.4% were in-field recurrences and another 19.4% were marginal recurrences.[41] These findings suggest that additional optimization of radiation therapy approaches are still needed.

Sources: 41

Treatment of bony metastatic disease, delivered at the time of primary tumor bed irradiation, is also considered to maximize disease control. Radiation therapy to metastatic disease sites is determined on an individual basis or according to protocol guidelines for patients enrolled in studies. Many children present with widespread bony metastases. Because it is not feasible to irradiate all initial sites, the current practice is to treat the sites that have not responded, as assessed by MIBG before HSCT.[42-44] Metastatic sites identified at diagnosis that did not receive radiation during frontline therapy appeared to have a higher risk of involvement at first relapse relative to previously irradiated metastatic sites.[42] In one single-institution study, 17 of 24 patients with residual MIBG-avid skeletal uptake at the end of front-line therapy without metastatic-site radiation therapy had disease recurrence. Of the 17 patients, 13 (76.5%) had disease recurrence at sites of prior skeletal disease.[45]

Sources: 42 · 44 · 42 · 45

In a retrospective series of 159 children with high-risk stage M neuroblastoma, focal irradiation was delivered to all metastatic sites, regardless of response to chemotherapy, unless metastases were too numerous.[46]

Sources: 46

The 5-year control rate of irradiated metastatic sites was 81%.

Metastases that became MIBG negative after chemotherapy were significantly less likely to recur than the sites that remained MIBG positive.

Patients whose disease did not relapse in their irradiated metastatic sites had improved OS.

When feasible to deliver radiation therapy, including to sites that resolved with induction chemotherapy, radiation therapy was more than 90% effective in providing disease control in those metastatic sites.

These observations support the current paradigm of irradiating metastases that persist by MIBG uptake after induction chemotherapy in high-risk patients. Irradiation of more than 50% of the bone marrow is not advised.[46]

Sources: 46

In cases where diffuse bone metastases remain after induction chemotherapy, high-dose chemotherapy is followed by reassessment before deciding on consolidative radiation therapy.

Preliminary outcomes of proton radiation therapy to treat patients with high-risk neuroblastoma primary tumors have been published, demonstrating acceptable efficacy and toxicity.[47]

Sources: 47

Health professional · Treatment of High-Risk Neuroblastoma / Treatment Options for High-Risk Neuroblastoma / Chemotherapy, surgery, tandem cycles of myeloablative therapy and HSCT, radiation therapy, and dinutuximab, with GM-CSF and isotretinoin

Postconsolidation phase

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Postconsolidation therapy is designed to treat potential MRD after HSCT.[31] For high-risk patients in remission after HSCT, dinutuximab combined with GM-CSF given together with isotretinoin demonstrated improved EFS.[48,49]

Sources: 31 · 48 · 49

Evidence (all treatments):

A randomized study compared high-dose therapy and purged autologous BMT with three cycles of intensive consolidation chemotherapy. In addition, after the completion of either chemotherapy or autologous BMT, patients were randomly assigned to stop therapy or to receive 6 months of isotretinoin. The EFS and OS results described below reflect outcome from the time of each randomization.[25]; [31][Level of evidence A1]

Sources: 25 · 31 · Level of evidence A1

A randomized study compared high-dose therapy and purged autologous BMT with three cycles of intensive consolidation chemotherapy. In addition, after the completion of either chemotherapy or autologous BMT, patients were randomly assigned to stop therapy or to receive 6 months of isotretinoin. The EFS and OS results described below reflect outcome from the time of each randomization.[25]; [31][Level of evidence A1]

The 5-year EFS rate was significantly better in the autologous BMT arm (30%), than in the consolidation chemotherapy arm (19%; P = .04). There was no significant difference in 5-year OS rates between the two arms (39% vs. 30%; P = .08).

Patients who received isotretinoin had a higher 5-year EFS rate than patients who received no maintenance therapy (42% vs. 31%), although the difference was not significant (P = .12).

The OS rate was higher for patients randomly assigned to receive isotretinoin (50%) than for those who stopped therapy (39%), but this difference was not significant (P = .10).

A retrospective, single-institution, nonrandomized trial compared patients who received GM-CSF and 3F8 anti-GD2 antibody therapy after either autologous HSCT or conventional chemotherapy.[50] The patients were a mixture of those referred for initial treatment or further therapy, and included patients with refractory and relapsed disease, some of whom had received autologous HSCT at referring institutions. In the autologous HSCT group, there was a significantly longer time from first chemotherapy or from autologous HSCT to initiation of GM-CSF and 3F8 anti-GD2 antibody treatment. The autologous HSCT group also had significantly more ultra–high-risk patients.

Sources: 50

A retrospective, single-institution, nonrandomized trial compared patients who received GM-CSF and 3F8 anti-GD2 antibody therapy after either autologous HSCT or conventional chemotherapy.[50] The patients were a mixture of those referred for initial treatment or further therapy, and included patients with refractory and relapsed disease, some of whom had received autologous HSCT at referring institutions. In the autologous HSCT group, there was a significantly longer time from first chemotherapy or from autologous HSCT to initiation of GM-CSF and 3F8 anti-GD2 antibody treatment. The autologous HSCT group also had significantly more ultra–high-risk patients.

A trend for better EFS with GM-CSF and 3F8 anti-GD2 antibody therapy and autologous HSCT was observed (65% vs. 51%, P = .128), but there was no statistically significant difference in OS between patients who were treated with chemotherapy alone and those who were treated with autologous HSCT.

In a COG phase III trial (ANBL0032 [NCT00026312]), participants who had previously undergone HSCT were randomly assigned to receive dinutuximab administered with GM-CSF and IL-2 in conjunction with isotretinoin, versus isotretinoin alone.[48]

Sources: ANBL0032 [NCT00026312] · 48

In a COG phase III trial (ANBL0032 [NCT00026312]), participants who had previously undergone HSCT were randomly assigned to receive dinutuximab administered with GM-CSF and IL-2 in conjunction with isotretinoin, versus isotretinoin alone.[48]

Immunotherapy together with isotretinoin (EFS rate, 66%) was superior to standard isotretinoin maintenance therapy (EFS rate, 46%). As a result, immunotherapy post-HSCT is considered the standard of care in COG trials for high-risk disease.

As a result of the COG studies, the U.S. Food and Drug Administration (FDA) approved dinutuximab.

Long-term follow-up (median follow-up time, 9.97 years; range, 0.7–15.3 years) was available for 226 eligible patients. The 5-year EFS rate was 56.6% (± 4.7%) for patients randomly assigned to receive immunotherapy (n = 114) versus 46.1% (± 5.1%) for those randomly assigned to receive isotretinoin only (n = 112) (P = .042). The 5-year OS rate was 73.2% (± 4.2%) for patients who received immunotherapy, versus 56.6% (± 5.1%) for patients who received isotretinoin (P = .045). Thirteen of 122 patients who received dinutuximab developed human anti-chimeric antibodies (HACA). Plasma levels of dinutuximab, HACA, and soluble IL-2 receptor-alpha did not correlate with EFS, OS, or clinically significant toxicity.[51][Level of evidence B1]

Sources: 51 · Level of evidence B1

After randomization was stopped for ANBL0032, all patients were assigned to receive immunotherapy. With longer follow-up data available for 1,183 patients, survival and toxicity results were similar to previous reports. For patients older than 18 months at diagnosis with International Neuroblastoma Staging System stage 4 disease (n = 662), the 5-year EFS rate was 57%, and the OS rate was 70.9%. Toxicities were similar to those reported for the randomized cohort. Among patients with available data, higher dinutuximab levels and Fc gamma receptor 3A (FCGR3A) genotype were associated with superior EFS.[52]

Sources: 52

Anti-GD2 antibodies, along with modulation of the immune system to enhance the antibody's antineuroblastoma activity, are often used to help treat patients with neuroblastoma. The clinical effectiveness of one such antibody led to the FDA approval of dinutuximab. The patient's response to immunotherapy may be caused, in part, by variation in immune function among patients. One anti-GD2 antibody, termed 3F8, used for treating neuroblastoma exclusively at one institution, directs natural killer cells to kill the neuroblastoma cells. However, the natural killer cells can be inhibited by the interaction of HLA antigens and killer immunoglobulin receptor (KIR) subtypes.[53,54] This finding was confirmed and expanded by an analysis of outcomes for patients treated in the national randomized COG-ANBL0032 (NCT00026312) study with the anti-GD2 antibody dinutuximab combined with GM-CSF and IL-2. The study found that certain KIR/KIR-ligand genotypes were associated with better outcomes for patients who were treated with immunotherapy.[55][Level of evidence A2] The presence of inhibitory KIR/KIR ligands was associated with a decreased effect of immunotherapy. Thus, the patient's immune system genes help determine response to immunotherapy for neuroblastoma. Additional studies are needed to determine whether this immune system genotyping can guide patient selection for certain immunotherapies.

Sources: 53 · 54 · COG-ANBL0032 (NCT00026312) · 55 · Level of evidence A2

A European study compared dinutuximab-beta (dinutuximab manufactured in hamster cells instead of mouse cells) to dinutuximab-beta plus subcutaneous (SQ) IL-2 administered as maintenance therapy after high-dose chemotherapy with autologous HSCT. All patients additionally received isotretinoin.[56]

Sources: 56

A European study compared dinutuximab-beta (dinutuximab manufactured in hamster cells instead of mouse cells) to dinutuximab-beta plus subcutaneous (SQ) IL-2 administered as maintenance therapy after high-dose chemotherapy with autologous HSCT. All patients additionally received isotretinoin.[56]

The addition of SQ IL-2 did not improve outcome. The 3-year EFS rate was 56% for patients treated with dinutuximab-beta and 60% for patients treated with dinutuximab-beta and SQ IL-2 (P = .76).

There was also no difference in incidence of relapse/progression or 5-year OS.

Patients treated with IL-2 had higher rates of fever, pain, allergic reaction, capillary leak syndrome, neurotoxicity, and gastrointestinal toxicity. In this study, only 62% of patients randomly assigned to the IL-2 arm received the planned therapy because of toxicity.

A second SIOPEN trial reported the following:[56]

Sources: 56

A second SIOPEN trial reported the following:[56]

Response rates and 2-year EFS and OS rates did not differ for patients treated with IL-2 versus no IL-2.

SIOPEN subsequently eliminated IL-2 from standard postconsolidation therapy.

A third randomized, phase II, SIOPEN trial compared treatment with IL-2 to treatment without IL-2.[57]

Sources: 57

A third randomized, phase II, SIOPEN trial compared treatment with IL-2 to treatment without IL-2.[57]

Response, EFS, and OS rates were not significantly different with IL-2 versus without IL-2, but toxicity was higher in the IL-2 arm.

Based on the SIOPEN data, the COG removed IL-2 from standard postconsolidation immunotherapy.

Radioactive MIBG therapy has been used to treat recurrent neuroblastoma with some success. This therapy has been shown to be safe and feasible to incorporate into the treatment regimen for children with newly diagnosed high-risk neuroblastoma.[58] A randomized trial (ANBL1531 [NCT03126916]) incorporating radioactive MIBG therapy into the complex therapy for newly diagnosed high-risk neuroblastoma has completed accrual.

Sources: 58 · ANBL1531 [NCT03126916]

A multi-institution, phase II clinical trial of children with high-risk neuroblastoma evaluated 2 years of continuation therapy using eflornithine (previously known as difluoromethylornithine [DFMO]), an oral ornithine decarboxylase inhibitor.[59] Although the study concluded that survival was improved compared with a subset of patients who were previously treated in the ANBL0032 (NCT00026312) trial, the historical comparison and potential patient selection bias limit the validity of this finding. An updated report describes the results of a propensity matching analysis that compared patients who were treated with eflornithine with patients in the ANBL0032 trial who were not treated with eflornithine.[60] Propensity matching generally balanced differences in available patient characteristics. In the matched analysis, patients in the eflornithine cohort had statistically significantly higher EFS and OS, compared with patients in the non-eflornithine cohort (4-year EFS rates, 84% vs. 73% and 4-year OS rates, 96% vs. 84%). The authors noted that uncontrolled confounders may exist in this nonrandomized comparison. Based on these results, the FDA approved the use of eflornithine as continuation therapy in December 2023.

Sources: 59 · ANBL0032 (NCT00026312) · 60

A GD2/GD3 ganglioside vaccine has been studied for patients in first remission after completion of standard therapy. In a randomized trial that mainly included patients in first remission, early introduction of beta-glucan along with a GD2/GD3 vaccine increased GD2/GD3 antibody titers without increasing toxicity. Progression-free survival (PFS) rates were similar for patients in both randomized treatment arms. However, patients with higher titers had more favorable PFS rates, regardless of the treatment arm.[61][Level of evidence B1]

Sources: 61 · Level of evidence B1

Health professional · Treatment of High-Risk Neuroblastoma

Treatment Options Under Clinical Evaluation

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

ANBL2131 (NCT06172296) (Dinutuximab with Chemotherapy, Surgery, and Stem Cell Transplant for the Treatment of Children With Newly Diagnosed High-Risk Neuroblastoma): This phase III randomized study seeks to determine if the early addition of dinutuximab (an anti-GD2 monoclonal antibody) plus GM-CSF to standard COG induction therapy improves EFS for patients with newly diagnosed high-risk neuroblastoma. All patients will receive the same induction cycle 1 while their tumors undergo centralized molecular testing as part of APEC14B1 Molecular Characterization Initiative. Patients will then be randomly assigned to receive either standard induction therapy or standard induction therapy with the addition of dinutuximab and GM-CSF.

Sources: ANBL2131 (NCT06172296)

Health professional

Treatment of INSS Stage 4S and INRG Stage MS Neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

International Neuroblastoma Staging System (INSS) stage 4S patients are younger than 12 months and have an INSS stage 1 or stage 2 primary tumor. International Neuroblastoma Risk Group (INRG) stage MS patients are younger than 18 months with any stage of primary tumor. Both staging systems have the same definition of limited pattern of metastases.

The decision by the INRG Task Force to replace the category of 4S disease with that of the new MS definition was based on reports in which small numbers of infants with L2 primary tumors and 4S metastatic patterns, including patients aged 12 to 18 months, had favorable outcomes.[1,2] A subsequent study of the actual INRG data found that a number of biological characteristics predicted poor outcome of patients aged 12 to 18 months with stage MS disease, and that only those infants with favorable biology had long-term outcomes similar to those with the traditional 4S diagnosis.[2]

Sources: 1 · 2 · 2

Infants with INRG stage MS disease have more favorable biology and superior outcomes despite receiving less aggressive therapy. The 5-year event-free survival (EFS) rate was 86%, and the overall survival (OS) rate was 95%. For patients with MYCN-amplified tumors, the 5-year EFS rate was 60%, and the OS rate was 65%.[3]

Sources: 3

Many patients with stage 4S/MS neuroblastoma do not require therapy. However, tumors with unfavorable biology or patients who are symptomatic because of evolving hepatomegaly and organ compromise are at increased risk of death and are treated with low-dose to moderate-dose chemotherapy. Eight percent to 10% of these patients will have MYCN amplification and are treated with high-risk treatment regimens.[4]

Sources: 4

For more information about the Children's Oncology Group (COG) classification schema for stage 4S/MS neuroblastoma, see Table 3.

Sources: Table 3

Health professional · Treatment of INSS Stage 4S and INRG Stage MS Neuroblastoma

Treatment Options for Stage 4S/MS Neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

There is no standard approach for the treatment of stage 4S/MS neuroblastoma.

Treatment options for stage 4S/MS neuroblastoma include the following:

Observation with supportive care (for asymptomatic patients with favorable tumor biology).

Sources: Observation with supportive care

Chemotherapy (for symptomatic patients or patients with unfavorable tumor biology).

Sources: Chemotherapy

Surgery (rarely, for patients with hepatomegaly that compromises the kidney or other abdominal organs).

Sources: Surgery

Radiation therapy (rarely, for patients with symptoms related to hepatomegaly from metastatic disease).

Sources: Radiation therapy

Resection of the primary tumor is not associated with improved outcome.[5-7] Rarely, infants with massive hepatic 4S/MS neuroblastoma develop cirrhosis from the chemotherapy and/or radiation therapy that is used to control the disease and may benefit from orthotopic liver transplant.[8]

Sources: 5 · 7 · 8

Health professional · Treatment of INSS Stage 4S and INRG Stage MS Neuroblastoma / Treatment Options for Stage 4S/MS Neuroblastoma

Observation with supportive care

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Observation with supportive care is used to treat asymptomatic patients with favorable tumor biology.

The treatment of children with stage 4S/MS disease depends on clinical presentation.[5,6] Most patients do not require therapy unless bulky disease causes organ compromise and risk of death.

Sources: 5 · 6

Health professional · Treatment of INSS Stage 4S and INRG Stage MS Neuroblastoma / Treatment Options for Stage 4S/MS Neuroblastoma

Chemotherapy

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Chemotherapy is used to treat symptomatic patients or patients with unfavorable tumor biology. Patients with evidence of rapid tumor growth in the first several weeks of life require immediate intervention with chemotherapy to avoid potentially irreversible abdominal compartment syndrome and hepatic and/or renal failure.[9]

Sources: 9

Infants diagnosed with INSS stage 4S/MS neuroblastoma, particularly those with hepatomegaly or those younger than 2 months with high-risk features or hepatomegaly, have the potential for rapid clinical deterioration and may benefit from early initiation of therapy.[9] It has been difficult to identify infants with stage 4S disease who will benefit from chemotherapy.

Sources: 9

A scoring system to measure signs and symptoms of deterioration or compromise was developed to better assess this group of stage 4S patients.[10] This scoring system has been evaluated retrospectively, was predictive of the clinical course, and has been applied prospectively to guide the management of patients with INSS stage 4S disease.[10,11] The scoring system has been modified based on the ANBL0531 (NCT00499616) study results in the youngest infants discussed above to guide chemotherapeutic intervention for 4S/MS in infants.[9]

Sources: 10 · 10 · 11 · ANBL0531 (NCT00499616) · 9

Various chemotherapy regimens (cyclophosphamide alone, carboplatin/etoposide, cyclophosphamide/doxorubicin/vincristine) have been used to treat symptomatic patients. The approach is to administer the chemotherapy only as long as symptoms persist to avoid toxicity, which contributes to poorer survival. Additionally, lower doses of chemotherapy are often recommended for very young or low-weight infants, along with granulocyte colony-stimulating factors after each cycle of chemotherapy.

Evidence (chemotherapy for 4S/MS disease):

The COG ANBL0531 (NCT00499616) trial prospectively studied a subset of 4S patients who had MYCN-nonamplified tumors with impaired or impending organ dysfunction or unfavorable biology (unfavorable histology and/or diploid DNA index [DI]). Forty-nine patients were enrolled, 41 of whom were symptomatic and 28 of whom had unfavorable biology. Patients were assigned to receive two, four, or eight cycles of chemotherapy based on the tumor biology, age of the patient, and symptoms.[9][Level of evidence C1]

Sources: ANBL0531 (NCT00499616) · 9 · Level of evidence C1

The COG ANBL0531 (NCT00499616) trial prospectively studied a subset of 4S patients who had MYCN-nonamplified tumors with impaired or impending organ dysfunction or unfavorable biology (unfavorable histology and/or diploid DNA index [DI]). Forty-nine patients were enrolled, 41 of whom were symptomatic and 28 of whom had unfavorable biology. Patients were assigned to receive two, four, or eight cycles of chemotherapy based on the tumor biology, age of the patient, and symptoms.[9][Level of evidence C1]

The 3-year OS rate was 81.4%.

Eight of the nine deaths occurred in patients younger than 2 months at diagnosis. Five deaths were related to acute complications of rapidly progressing hepatomegaly (i.e., abdominal compartment syndrome, renal failure, respiratory failure, coagulopathy, and infection). Patients younger than 40 days at diagnosis had more than 13 times the risk of dying compared with patients older than 47 days. The study was amended after the five deaths to mandate immediate chemotherapy for patients with 4S disease younger than 2 months at diagnosis with evolving hepatomegaly. No deaths related to complications of hepatomegaly occurred in the subsequent infants enrolled, including 18 infants who were younger than 2 months.

This study confirmed the inferior outcome of patients with unfavorable biology (DI = 1, segmental chromosome aberrations [1p and/or 11p loss of heterozygosity, unfavorable histology] without MYCN amplification) compared with symptomatic patients with favorable biology.

Both of the patients with late death died of metastatic disease and had unfavorable biology.

Eighty patients with stage 4S disease were enrolled on the COG-P9641 (NCT00003119) trial. Forty-one patients with asymptomatic stage 4S neuroblastoma were treated with surgery or biopsy alone, and 39 patients were treated with surgery and chemotherapy.[12]

Sources: COG-P9641 (NCT00003119) · 12

Eighty patients with stage 4S disease were enrolled on the COG-P9641 (NCT00003119) trial. Forty-one patients with asymptomatic stage 4S neuroblastoma were treated with surgery or biopsy alone, and 39 patients were treated with surgery and chemotherapy.[12]

Overall, the 5-year EFS rate was 77%, and the OS rate was 91%.

The 5-year EFS rate was 63% for patients treated with surgery or biopsy alone and 95% for patients treated with surgery and chemotherapy (P = .0016).

The 5-year OS rate was 84% for patients treated with surgery or biopsy alone and 97% for patients treated with surgery and chemotherapy (P = .1302).Previously, chemotherapy toxicity was thought to be responsible for the poorer survival of patients with stage 4S disease. However, the use of chemotherapy on the COG-P9641 trial was restricted to specific clinical situations with a recommended number of cycles.

Also, on the COG-P9641 trial, asymptomatic infants with biologically favorable (MYCN-nonamplified) INSS stage 4S disease did not receive chemotherapy until the development of progressive disease or clinical symptoms.[12]

Sources: 12

Also, on the COG-P9641 trial, asymptomatic infants with biologically favorable (MYCN-nonamplified) INSS stage 4S disease did not receive chemotherapy until the development of progressive disease or clinical symptoms.[12]

Infants who became symptomatic had disease-related organ failure and infectious complications, resulting in an inferior OS compared with those who received immediate chemotherapy (4–8 cycles of therapy). The 3-year OS rate was 84% for infants who did not receive chemotherapy versus 97% for infants who received chemotherapy (P = .1321).

For the COG-ANBL0531 trial, treatment was allocated based on symptoms, patient age, and tumor biology.[9]

Sources: COG-ANBL0531 · 9

For the COG-ANBL0531 trial, treatment was allocated based on symptoms, patient age, and tumor biology.[9]

The 2-year OS rate was 81% for patients with INSS stage 4S disease, which is lower than that reported in other cooperative trials such as COG-P9641.

Many patients enrolled in the ANBL0531 study were more ill than patients entered in previous trials, in part because tumor biopsy was not required in symptomatic infants. Previous trials mainly included asymptomatic patients, most with favorable tumor biology.

A prospective study was performed in 125 infants with stage 4S MYCN-nonamplified tumors or INSS stage 3 primary tumors and/or positive bone scintigraphy not associated with changes in the cortical bone (documented on plain radiographs and/or computed tomography).[11] A pretreatment symptom score was used to determine initial treatment. Observation was recommended for infants with low symptom scores (n = 86), and chemotherapy was recommended for infants with high symptom scores (n = 37). The chemotherapy for patients with high symptom scores included two to four 3-day courses of carboplatin and etoposide. If symptoms persisted or progressive disease developed, up to four 5-day courses of cyclophosphamide, doxorubicin, and vincristine were administered. One-half of the patients underwent complete or partial resection of the primary tumor.

Sources: 11

A prospective study was performed in 125 infants with stage 4S MYCN-nonamplified tumors or INSS stage 3 primary tumors and/or positive bone scintigraphy not associated with changes in the cortical bone (documented on plain radiographs and/or computed tomography).[11] A pretreatment symptom score was used to determine initial treatment. Observation was recommended for infants with low symptom scores (n = 86), and chemotherapy was recommended for infants with high symptom scores (n = 37). The chemotherapy for patients with high symptom scores included two to four 3-day courses of carboplatin and etoposide. If symptoms persisted or progressive disease developed, up to four 5-day courses of cyclophosphamide, doxorubicin, and vincristine were administered. One-half of the patients underwent complete or partial resection of the primary tumor.

There was no difference in the 2-year EFS and OS between asymptomatic and symptomatic patients (EFS rate, 87% vs. 88%; OS rate, 98% vs. 97%), although many of the investigators preferred to give chemotherapy in the presence of a low symptom score.

For infants with low symptom scores, there was no difference in the outcome between the initially untreated infants (n = 56; OS rate, 93%) and treated infants (n = 30; OS rate, 86%).

The OS rate was 90% for infants presenting with high symptom scores.

There was no significant difference in 2-year OS rates between patients with unresectable primary tumors and patients with resectable primary tumors (97% vs. 100%) and between patients with negative and positive skeletal scintigraphy without radiological abnormalities (100% vs. 97%).

Health professional · Treatment of INSS Stage 4S and INRG Stage MS Neuroblastoma / Treatment Options for Stage 4S/MS Neuroblastoma

Surgery

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Occasionally, if the liver becomes too large and is compromising the kidney and other abdominal organs, a decompressive laparotomy may be necessary,[13,14] although this would typically be an indication for chemotherapy as well. Likewise, emergent surgical abdominal decompression can be used to avoid respiratory deterioration and improve ventilation.[13,14]

Sources: 13 · 14 · 13 · 14

Health professional · Treatment of INSS Stage 4S and INRG Stage MS Neuroblastoma / Treatment Options for Stage 4S/MS Neuroblastoma

Radiation therapy

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

In rare cases of marked hepatomegaly in symptomatic MS (4S) infants with neuroblastoma who were unresponsive to chemotherapy, very low-dose radiation therapy has been used. In a series of 41 symptomatic infants with MS disease, radiation therapy was administered to five infants, three of whom died.[9]

Sources: 9

Health professional · Treatment of INSS Stage 4S and INRG Stage MS Neuroblastoma

Treatment Options Under Clinical Evaluation

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

Health professional

Treatment of Recurrent or Refractory Neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Tumor growth resulting from maturation should be differentiated from tumor progression by performing a biopsy and reviewing histology. Patients may have persistent maturing disease with metaiodobenzylguanidine (MIBG) uptake that does not affect outcome, particularly patients with low-risk and intermediate-risk disease.[1] An analysis of 23 paired MIBG and positron emission tomography (PET) scans in 14 patients with refractory or recurrent high-risk neuroblastoma treated with iodine I 131-MIBG (131I-MIBG) found that the MIBG scan was more sensitive than fluorine F 18-fludeoxyglucose (18F-FDG) PET for detecting metastatic bone lesions, although there was a trend for 18F-FDG PET to be more sensitive for soft tissue lesions.[2]

Sources: 1 · 2

Subclonal ALK variants or other MAPK pathway lesions may be present at diagnosis, with subsequent clonal expansion at relapse. Consequently, serial sampling of progressive tumors may lead to the identification of potentially actionable variants.[3,4] Modern comprehensive molecular analysis comparing primary and relapsed neuroblastoma from the same patients revealed extensive clonal enrichment and several newly discovered variants, with many tumors showing new or clonal-enriched variants in the RAS-MAPK pathway. This was true for patients with both high-risk and low-risk tumors at diagnosis.[5,6] For more information, see the Genomic and Biological Features of Neuroblastoma section.

Sources: 3 · 4 · 5 · 6 · Genomic and Biological Features of Neuroblastoma

Sequencing of recurrent and refractory neuroblastoma tumors from pediatric (n = 59) and young adult patients (n = 1) enrolled in the NCI-COG Pediatric MATCH trial revealed genomic alterations that were considered actionable for treatment in MATCH study arms in 27 of 60 tumors (45%).[7] Hotspot variants in ALK were most frequent, reported in 19 of 60 tumors (31.7%). MAPK pathway variants (NF1, NRAS) were detected in 4 of 60 tumors (6.7%), and FGFR1 variants were detected in 3 of 60 tumors (5%).

Sources: 7

If neuroblastoma recurs in a child originally diagnosed with high-risk disease, the prognosis is usually poor despite additional intensive therapy.[8-11] However, it is often possible to gain many additional months of life for these patients with alternative chemotherapy regimens.[12,13] Clinical trials are appropriate for these patients and may be offered. Information about ongoing clinical trials is available from the NCI website.

Sources: 8 · 11 · 12 · 13 · NCI website

Health professional · Treatment of Recurrent or Refractory Neuroblastoma

Prognostic Factors in Patients With Recurrent Neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

A comprehensive analysis of the patterns of relapse was conducted using the International Neuroblastoma Risk Group (INRG) database on patients diagnosed/enrolled between 1989 and 2017.[14][Level of evidence C1]

Sources: 14 · Level of evidence C1

For 1,833 children, the pattern of first relapse included isolated local (19%), distant only (65%), and combined sites (16%).

Patients with isolated local failure had more favorable prognostic features.

Patients with stage 3 disease were more likely to have isolated local failure than patients with all other stages (49% vs. 16%, P < .001).

The 5-year overall survival (OS) rates significantly differed by relapse pattern, with a rate of 64% for isolated local, 23% for distant only, and 26% for combined sites (P < .001).

After controlling for age, stage, and MYCN status, patients with isolated local failure (adjusted hazard ratio [HR], 0.46; P < .001) and distant-only failure (adjusted HR, 0.57; P < .001) remained at decreased risk of death, compared with patients with combined failure.

The INRG database was used to examine clinical and biological features that are prognostic of survival after relapse or progression of INRG Staging System (INRGSS) stage MS pattern neuroblastoma. Of the 1,511 patients diagnosed between 1984 and 2021 who met the eligibility criteria, 209 patients were identified as having an event. Eligibility criteria included patients younger than 365 days at initial diagnosis with INRGSS stage MS disease or with International Neuroblastoma Staging System (INSS) stage 4S, or patients aged 365 to 546 days with INSS stage 4 disease and metastasis limited to the liver, skin, and/or bone marrow.[15][Level of evidence C1]

Sources: 15 · Level of evidence C1

In this group, the median time to first event was 8.16 months.

Most relapses had a component of metastatic failure. These metastases more commonly occurred at sites outside of the liver, skin, and bone marrow.

The 5-year OS rate was 62% for patients treated in 2001 and later.

The International Neuroblastoma Risk Group Project performed a survival-tree analysis of clinical and biological characteristics (defined at diagnosis) associated with survival after relapse in 2,266 patients with neuroblastoma entered in large clinical trials in well-established clinical trials groups around the world.[8] The survival-tree analysis revealed the following:

Sources: 8

The OS rate was 20% in the entire population with relapsed disease.

Among patients with all stages of disease at diagnosis, MYCN amplification predicted a poorer prognosis, measured as 5-year OS.

Among patients diagnosed with INSS stage 4 without MYCN amplification, age older than 18 months and high lactate dehydrogenase (LDH) level predicted poor prognosis.

Among patients with MYCN amplification, those diagnosed with stage 1 and stage 2 disease had a better prognosis than those diagnosed with stage 3 and stage 4 disease.

Among patients with MYCN-nonamplified tumors who were not stage 4, patients with hyperdiploidy had a better prognosis than patients with diploidy in those younger than 18 months. Among those older than 18 months, patients with differentiating tumors fared much better than patients with undifferentiated and poorly differentiated tumors.

Significant prognostic factors determined at diagnosis for postrelapse survival include the following:[8]

Sources: 8

Age.

INSS stage.

MYCN status.

Time from diagnosis to first relapse.

LDH level, ploidy, and histological grade of tumor differentiation (to a lesser extent).

The Children’s Oncology Group (COG) experience with recurrence in patients with low-risk and intermediate-risk neuroblastoma showed that most patients can be salvaged. The COG reported a 3-year event free survival (EFS) rate of 88% and an OS rate of 96% in intermediate-risk patients and a 5-year EFS rate of 89% and OS rate of 97% in low-risk patients.[16,17] Moreover, in most patients originally diagnosed with low-risk or intermediate-risk disease, local recurrence or recurrence in the 4S pattern may be treated successfully with observation alone, surgery alone, or with moderate-dose chemotherapy, without myeloablative therapy and stem cell transplant.

Sources: 16 · 17

The OS after recurrence in children presenting with high-risk neuroblastoma is generally extremely poor. However, such patients at first relapse after complete remission or minimal residual disease (MRD) in whom relapse was a single site of soft tissue mass (a few children also had bone marrow or bone disease at relapse) had a 5-year OS rate of 35% in one single-institution study. All patients underwent surgical resection of the soft tissue disease. MYCN amplification and multifocal soft tissue disease were associated with a worse postprogression survival.[18] Older children with local recurrence, with either unfavorable International Neuroblastoma Pathology Classification at diagnosis or MYCN gene amplification, have a poor prognosis and may be treated with surgery or aggressive combination chemotherapy, or they may be offered entry into a clinical trial.

Sources: 18

Table 7 summarizes the treatment options for recurrent neuroblastoma by INSS-based risk group.

Sources: Table 7

Table 7. Treatment Options for Recurrent Neuroblastoma
COG Risk-Group AssignmentTreatment Options
COG = Children's Oncology Group; 131I-MIBG = iodine I 131-metaiodobenzylguanidine.
Locoregional recurrence in patients initially classified as low riskSurgery followed by observation or chemotherapy.
Chemotherapy that may be followed by surgery.
Metastatic recurrence in patients initially classified as low riskObservation (if metastatic disease is in a 4S pattern in an infant).
Chemotherapy.
Surgery followed by chemotherapy.
Locoregional recurrence in patients initially classified as intermediate riskSurgery (complete resection).
Surgery (incomplete resection) followed by chemotherapy.
Radiation therapy (only for patients with disease progression after chemotherapy and second-look surgery).
Metastatic recurrence in patients initially classified as intermediate riskHigh-risk therapy.
Recurrence in patients initially classified as high riskChemotherapy combined with immunotherapy.
131I-MIBG alone, in combination with other therapy, followed by stem cell rescue.
Novel therapies, including ALK inhibitors for those patients with ALK variants.
Chemotherapy.
Immunotherapy.
Recurrence in the central nervous systemSurgery and radiation therapy.
Chemotherapy in combination with surgery and radiation therapy.
Novel therapeutic approaches.

Sources: Surgery followed by observation or chemotherapy · Chemotherapy that may be followed by surgery · Observation · Chemotherapy · Surgery followed by chemotherapy · Surgery · Surgery (incomplete resection) followed by chemotherapy · Radiation therapy · High-risk therapy · Chemotherapy combined with immunotherapy · 131I-MIBG alone, in combination with other therapy, followed by stem cell rescue · Novel therapies, including ALK inhibitors for those patients with ALK variants · Chemotherapy · Immunotherapy · Surgery and radiation therapy · Chemotherapy in combination with surgery and radiation therapy · Novel therapeutic approaches

Health professional · Treatment of Recurrent or Refractory Neuroblastoma

Recurrent Neuroblastoma in Patients Initially Classified as Low Risk

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Health professional · Treatment of Recurrent or Refractory Neuroblastoma / Recurrent Neuroblastoma in Patients Initially Classified as Low Risk

Locoregional recurrence

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Treatment options for locoregional recurrent neuroblastoma initially classified as low risk include the following:

Surgery followed by observation or chemotherapy.

Chemotherapy that may be followed by surgery.

Local or regional recurrent cancer is resected if possible.

Patients with favorable biology and regional recurrence more than 3 months after completion of planned treatment are observed if resection of the recurrence is total or near total (≥90% resection). Those with favorable biology and a less-than-near-total resection are treated with chemotherapy.[16,17,19]

Sources: 16 · 17 · 19

Infants younger than 1 year at the time of locoregional recurrence whose tumors have any unfavorable biological properties are observed if resection is total or near total. If the resection is less than near total, these infants are treated with chemotherapy. Chemotherapy may consist of moderate doses of carboplatin, cyclophosphamide, doxorubicin, and etoposide, or cyclophosphamide and topotecan. The cumulative dose of each agent is kept low to minimize long-term effects, as used in previous COG trials (COG-P9641 and COG-A3961).[16,17,19]

Sources: COG-P9641 · COG-A3961 · 16 · 17 · 19

Evidence (surgery followed by observation or chemotherapy):

A COG study of low-risk patients with stages 1, 2A, 2B, and 4S neuroblastoma enrolled 915 patients, 800 of whom were asymptomatic and treated with surgery alone followed by observation. The other patients received chemotherapy with or without surgery.[17]

Sources: 17

A COG study of low-risk patients with stages 1, 2A, 2B, and 4S neuroblastoma enrolled 915 patients, 800 of whom were asymptomatic and treated with surgery alone followed by observation. The other patients received chemotherapy with or without surgery.[17]

About 10% of patients developed progressive or recurrent tumors.

Most recurrences were treated during the study with surgery alone or moderate chemotherapy with or without surgery.

Most patients' disease was salvaged, as demonstrated by the EFS (89%) and OS (97%) rates at 5 years.

Health professional · Treatment of Recurrent or Refractory Neuroblastoma / Recurrent Neuroblastoma in Patients Initially Classified as Low Risk

Metastatic recurrence or disease refractory to standard treatment

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Treatment options for metastatic recurrent neuroblastoma initially classified as low risk include the following:

Observation.

Chemotherapy (based on age of patient, tumor biology, and prior treatment; treatment may include intermediate-risk or high-risk therapies, as used at initial diagnosis).

Surgery followed by chemotherapy.

Metastatic recurrent or progressive neuroblastoma in an infant initially categorized as low risk and younger than 1 year at recurrence may be treated according to tumor biology, as defined in the previous COG trials (COG-P9641 and COG-A3961):

Sources: COG-P9641 · COG-A3961

If the biology is completely favorable, metastasis is in a 4S pattern, and the recurrence or progression is within 3 months of diagnosis, the patient is observed symptomatically.

If the metastatic progression or recurrence occurs more than 3 months after diagnosis or not in a 4S pattern, then the primary tumor is resected, if possible, and chemotherapy is given. Chemotherapy may consist of moderate doses of carboplatin, cyclophosphamide, doxorubicin, and etoposide. The cumulative dose of each agent is kept low to minimize long-term effects, as used in previous COG trials (COG-P9641 and COG-A3961).

Any child initially categorized as low risk who is older than 18 months at the time of metastatic recurrent or progressive disease and whose recurrence is not in the stage 4S pattern usually has a poor prognosis and is treated as follows:

High-risk therapy.

Patients with metastatic recurrent neuroblastoma are treated like patients with newly diagnosed high-risk neuroblastoma. For more information, see the Treatment Options for High-Risk Neuroblastoma section.

Sources: Treatment Options for High-Risk Neuroblastoma

Health professional · Treatment of Recurrent or Refractory Neuroblastoma

Recurrent Neuroblastoma in Patients Initially Classified as Intermediate Risk

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

The COG ANBL0531 (NCT00499616) study treated patients with newly diagnosed intermediate-risk neuroblastoma with chemotherapy consisting of carboplatin, etoposide, cyclophosphamide, and doxorubicin. Retrieval therapy was included in the protocol for patients who developed progressive nonmetastatic disease within 3 years of study enrollment. Up to six cycles of cyclophosphamide and topotecan could be given to patients. Of 29 patients who received cyclophosphamide and topotecan, 18 remained event free, 9 experienced relapse, and 2 died. Twenty patients who experienced an inadequate initial response to eight cycles of chemotherapy were treated with cyclophosphamide and topotecan. Of those 20 patients, 9 patients achieved a very good partial response or better; however, 6 patients developed progressive disease or experienced relapse, and 1 patient died. This suggests that more aggressive therapy is needed for patients who do not achieve the defined treatment end point after eight cycles of chemotherapy.[19]

Sources: ANBL0531 (NCT00499616) · 19

A COG study for intermediate-risk neuroblastoma (COG-A3961) enrolled 479 patients, 42 of whom developed disease progression. The recurrence rate was 10% for those with favorable biology and 17% for those with unfavorable biology. Thirty patients had locoregional recurrences, 11 had metastatic recurrences, and 1 had both types of recurrent disease. Six of the 42 patients died of disease, while 36 patients responded to therapy. Thus, most patients with intermediate-risk neuroblastoma and disease progression may be salvaged.[16] It is not feasible to compare these results with the results of the other COG intermediate-risk study (ANBL0531) because of differences between the classification of patients for eligibility in the two studies.[19]

Sources: COG-A3961 · 16 · 19

Health professional · Treatment of Recurrent or Refractory Neuroblastoma / Recurrent Neuroblastoma in Patients Initially Classified as Intermediate Risk

Locoregional recurrence

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Treatment options for locoregional recurrent neuroblastoma initially classified as intermediate risk include the following:

Surgery (complete resection).

Surgery (incomplete resection) followed by chemotherapy.

Radiation therapy. Radiation therapy is considered only for patients with disease progression after chemotherapy and second-look surgery.[16]

Sources: 16

Locoregional recurrence of neuroblastoma with favorable biology that occurs more than 3 months after completion of chemotherapy may be treated surgically. If resection is less than near total, then additional chemotherapy may be given. Chemotherapy should be selected based on the previous chemotherapy received.[16]

Sources: 16

Health professional · Treatment of Recurrent or Refractory Neuroblastoma / Recurrent Neuroblastoma in Patients Initially Classified as Intermediate Risk

Metastatic recurrence

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Treatment options for metastatic recurrent neuroblastoma initially classified as intermediate risk include the following:

High-risk therapy.

Patients with metastatic recurrent neuroblastoma are treated like patients with newly diagnosed high-risk neuroblastoma. For more information, see the Treatment Options for High-Risk Neuroblastoma section.

Sources: Treatment Options for High-Risk Neuroblastoma

Health professional · Treatment of Recurrent or Refractory Neuroblastoma

Recurrent or Refractory Neuroblastoma in Patients Initially Classified as High Risk

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Any recurrence in patients initially classified as high risk signifies a very poor prognosis.[8] Clinical trials may be considered. Palliative care should also be considered as part of the patient's treatment plan.

Sources: 8

An analysis of several trials included 383 patients with neuroblastoma whose tumor recurred or progressed in COG modern-era, early-phase trials. The 1-year progression-free survival (PFS) rate was 21%, and the 4-year PFS rate was 6%. The OS rates were 57% at 1 year and 20% at 4 years. Less than 10% of patients experienced no subsequent recurrence or progression. MYCN amplification predicted worse PFS and OS rates.[20] Although the OS after recurrence in children presenting with high-risk neuroblastoma is generally extremely poor, patients with high-risk neuroblastoma at first relapse after complete remission or MRD in whom relapse was a single site of soft tissue mass (a few children also had bone marrow or bone disease at relapse) had a 5-year OS rate of 35% in one single-institution study.[18]

Sources: 20 · 18

Treatment options for recurrent or refractory neuroblastoma in patients initially classified as high risk include the following:

Chemotherapy combined with immunotherapy.

Chemotherapy combined with immunotherapy.

Temozolomide, irinotecan, and dinutuximab.[21]

Sources: 21

131I-MIBG. 131I-MIBG alone, in combination with other therapy, followed by stem cell rescue.

Novel therapies.

Novel therapies.

ALK inhibitors for patients with ALK variants. In a trial of 20 patients with ALK aberrations treated with crizotinib, the response rate was 15%. Two patients had partial responses, and one patient had a complete response. All three patients had a somatic ALK Arg1275Gln variant.[22][Level of evidence C3] Lorlatinib has shown activity in patients with ALK-aberrant, relapsed neuroblastoma. The response rates were 13% in patients younger than 18 years and 47% in patients aged 18 years or older.[23] Additional patients in each cohort had minor responses, resulting in modified response rates of 30% and 67%, respectively. A single-institution series reported that 9 of 13 adult patients with relapsed, ALK-aberrant neuroblastoma responded to lorlatinib.[24]

Sources: 22 · Level of evidence C3 · 23 · 24

WEE1 inhibitors. A phase II trial of adavosertib plus irinotecan reported that 3 of 20 patients with relapsed neuroblastoma had objective responses, which met the primary efficacy end point.[25]

Sources: 25

Bevacizumab. The BEACON trial was a multiarm randomized trial with a factorial design for patients with relapsed or refractory high-risk neuroblastoma. Eighty patients were assigned to receive chemotherapy with the addition of bevacizumab and 80 patients were assigned to receive chemotherapy alone.[26] Patients randomly assigned to receive bevacizumab had a higher response rate (26% vs. 18%) that met a prespecified threshold for success. The 1-year PFS rate was nominally higher for patients who received bevacizumab (46% with bevacizumab vs. 38% for those who did not receive bevacizumab; HR, 0.89; 95% confidence interval [CI], 0.63–1.27). There was evidence for an interaction with the chemotherapy randomization (see below), such that patients randomly assigned to bevacizumab, irinotecan, and temozolomide had the most favorable 1-year PFS rates (67%).

Sources: 26 · below

RIST regimen. A randomized phase II trial included 129 patients with relapsed or refractory neuroblastoma. The study compared the combination of dasatinib and rapamycin added to irinotecan and temozolomide (RIST regimen) with irinotecan and temozolomide alone. In the full cohort, the median PFS was significantly longer in the RIST group (11 months) than in the chemotherapy-alone group (5 months; HR, 0.62; P = .019). On subgroup analysis, the benefit was largely seen in patients with MYCN-amplified disease (median PFS, 6 months with RIST vs. 2 months with control; HR, 0.45; P = .012) and not in patients with MYCN wild-type disease (median PFS, 14 months with RIST vs. 8 months with control; HR, 0.84; P = .49).[27]

Sources: 27

Chemotherapy (phase I/II studies).

Chemotherapy (phase I/II studies).

Topotecan in combination with cyclophosphamide or etoposide.[28]

Sources: 28

Temozolomide with irinotecan.

Immunotherapy. Novel anti-GD2 drugs have been evaluated in patients with recurrent or refractory neuroblastoma. Hu14.18 anti-GD2 has been chemically linked with IL-2 and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), and a phase II trial of this regimen reported a few durable responses.[29]

Sources: 29

Chemotherapy combined with immunotherapy produces the best response rate and response duration of treatments for high-risk patients with disease progression.

Evidence (chemotherapy combined with immunotherapy):

The ANBL1221 (NCT01767194) trial was the first multicenter trial to evaluate anti-GD2 therapy combined with chemotherapy in a cohort of patients with relapsed or refractory neuroblastoma. Patients in first relapse or progression were randomly assigned to receive either irinotecan/temozolomide/dinutuximab/GM-CSF (I/T/DIN/GM-CSF) or temozolomide/irinotecan/temsirolimus.[21]; [30][Level of evidence C3]

Sources: ANBL1221 (NCT01767194) · 21 · 30 · Level of evidence C3

The ANBL1221 (NCT01767194) trial was the first multicenter trial to evaluate anti-GD2 therapy combined with chemotherapy in a cohort of patients with relapsed or refractory neuroblastoma. Patients in first relapse or progression were randomly assigned to receive either irinotecan/temozolomide/dinutuximab/GM-CSF (I/T/DIN/GM-CSF) or temozolomide/irinotecan/temsirolimus.[21]; [30][Level of evidence C3]

Of the 17 patients treated with the combination that included dinutuximab, 9 patients (53%) had objective responses, compared with 1 of 18 patients treated with the regimen that contained temsirolimus.

In an expansion cohort consisting of 36 additional patients nonrandomly assigned to receive I/T/DIN/GM-CSF, objective responses were seen in 13 patients (36.1%). For all 53 patients enrolled on the study and treated with I/T/DIN/GM-CSF, there were 22 objective responses (41.5%).[30][Level of evidence C3] This outcome is superior to any other published outcome for patients with refractory or relapsed high-risk neuroblastoma.

Sources: 30 · Level of evidence C3

In a retrospective cohort study of 146 patients with high-risk neuroblastoma who received chemoimmunotherapy with I/T/DIN/GM-CSF in first relapse, the following results were reported:[31][Level of evidence C2]

Sources: 31 · Level of evidence C2

In a retrospective cohort study of 146 patients with high-risk neuroblastoma who received chemoimmunotherapy with I/T/DIN/GM-CSF in first relapse, the following results were reported:[31][Level of evidence C2]

A total of 49% of patients had an objective response, similar to the response rate seen in the ANBL1221 trial.

Of the patients with stable disease or better at first disease evaluation after chemoimmunotherapy, 22% had an improved response (per International Neuroblastoma Response Criteria) on subsequent evaluation. Only 13% of patients with stable disease at first disease evaluation eventually had an objective response, whereas approximately 40% of patients with initial minimal response or partial response status achieved complete response after subsequent cycles. Patients who received more than six cycles of therapy and had continued stable disease were unlikely to achieve an objective response.

The median PFS was 13.1 months from initiation of therapy. The 1-year PFS rate was 50%, and the 2-year PFS rate was 28%.

The median duration of response was 15.9 months.

The median PFS after discontinuation of all anticancer therapy, including I/T/DIN/GM-CSF, was 10.4 months.

Limited data are available about the use of chemotherapy backbones other than irinotecan/temozolomide as part of a chemoimmunotherapy strategy. A registry study included 24 patients with relapsed or progressive high-risk neuroblastoma who were treated with topotecan/cyclophosphamide and dinutuximab.[32]

Sources: 32

Limited data are available about the use of chemotherapy backbones other than irinotecan/temozolomide as part of a chemoimmunotherapy strategy. A registry study included 24 patients with relapsed or progressive high-risk neuroblastoma who were treated with topotecan/cyclophosphamide and dinutuximab.[32]

The objective response rate was 42%.

Evidence (131I-MIBG alone or in combination with other therapies):

For children with recurrent or refractory neuroblastoma, 131I-MIBG is an effective palliative agent and may be considered alone or in combination with chemotherapy and stem cell support in a clinical research trial.[33-38]; [39,40][Level of evidence C1]

Sources: 33 · 38 · 39 · 40 · Level of evidence C1

A North American retrospective study of more than 200 patients treated with 131I-MIBG therapy compared children who had recurrence or progression of disease with children who had stable or persistent disease since diagnosis.[41]

Sources: 41

A North American retrospective study of more than 200 patients treated with 131I-MIBG therapy compared children who had recurrence or progression of disease with children who had stable or persistent disease since diagnosis.[41]

The rate of immediate progression after 131I-MIBG therapy was lower, and the OS rate at 2 years was better (65% vs. 39%) in patients with stable, persistent disease.

Tandem consolidation using 131I-MIBG, vincristine, and irinotecan with autologous hematopoietic stem cell transplant (HSCT) followed by busulfan/melphalan with autologous HSCT was retrospectively reported in eight patients.[40]

Sources: 40

Tandem consolidation using 131I-MIBG, vincristine, and irinotecan with autologous hematopoietic stem cell transplant (HSCT) followed by busulfan/melphalan with autologous HSCT was retrospectively reported in eight patients.[40]

This treatment resulted in three complete responses, two partial responses, and one minor response.

Single autologous HSCT with 131I-MIBG and carboplatin/etoposide/melphalan was studied in additional patients. Patients were treated after completing induction chemotherapy.[42]

Sources: 42

Single autologous HSCT with 131I-MIBG and carboplatin/etoposide/melphalan was studied in additional patients. Patients were treated after completing induction chemotherapy.[42]

Response to induction therapy included refractory disease in 27 patients and progressive disease in 15 patients. Four of 41 evaluable patients had complete or partial responses after transplant. Eight patients with partial responses to induction therapy were treated, resulting in three responses.

There was a 12% incidence of sinusoidal obstructive syndrome.

A randomized phase II trial included 105 evaluable patients who were treated with either 131I-MIBG alone, 131I-MIBG with irinotecan and vincristine, or 131I-MIBG with vorinostat.[43]

Sources: 43

A randomized phase II trial included 105 evaluable patients who were treated with either 131I-MIBG alone, 131I-MIBG with irinotecan and vincristine, or 131I-MIBG with vorinostat.[43]

Patients enrolled in the vorinostat arm had the highest response rate (32%).

Patients treated with MIBG alone or with irinotecan/vincristine had response rates of 14%.

A single-arm, phase II trial included 30 patients with relapsed or refractory neuroblastoma who were treated with 131I-MIBG and topotecan.[44]

Sources: 44

A single-arm, phase II trial included 30 patients with relapsed or refractory neuroblastoma who were treated with 131I-MIBG and topotecan.[44]

A 13% response rate was reported.

131I-MIBG is associated with risk of second malignancy. In one report of 563 5-year survivors of neuroblastoma, 15.5% had received prior 131I-MIBG therapy.[45]

Sources: 45

131I-MIBG is associated with risk of second malignancy. In one report of 563 5-year survivors of neuroblastoma, 15.5% had received prior 131I-MIBG therapy.[45]

The risk of a second malignant neoplasm was higher for patients treated with prior 131I-MIBG, compared with survivors who were not treated with 131I-MIBG (sub-hazard ratio, 5.7; 95% CI, 1.8–17.8).

Evidence (chemotherapy):

Irinotecan and temozolomide.

Irinotecan and temozolomide.

The combination of irinotecan and temozolomide had a 15% response rate in one study.[46][Level of evidence B4]

Sources: 46 · Level of evidence B4

In the BEACON trial, patients were randomly assigned to receive either temozolomide or irinotecan and temozolomide, with or without bevacizumab, in a factorial trial design.[26]

Sources: 26

Irinotecan and temozolomide. › In the BEACON trial, patients were randomly assigned to receive either temozolomide or irinotecan and temozolomide, with or without bevacizumab, in a factorial trial design.[26]

Response rates were similar in the two treatment groups (21% with temozolomide vs. 20% with irinotecan and temozolomide).

The 1-year PFS rate was superior for patients who were treated with irinotecan and temozolomide (53%), compared with temozolomide (30%; HR, 0.59; 95% CI, 0.39–0.90).

A retrospective study reported on 74 patients who received 92 cycles of ifosfamide, carboplatin, and etoposide. The study included 37 patients who received peripheral blood stem cell rescue after responding to this drug combination.[47]

Sources: 47

A retrospective study reported on 74 patients who received 92 cycles of ifosfamide, carboplatin, and etoposide. The study included 37 patients who received peripheral blood stem cell rescue after responding to this drug combination.[47]

Disease regressions (major and minor responses) were achieved in 14 of 17 patients (82%) with a new relapse, 13 of 26 patients (50%) with refractory neuroblastoma, and 12 of 34 patients (35%) who were treated for progressive disease during chemotherapy (P = .005).

Grade 3 toxicities were rare.

Topotecan in combination with cyclophosphamide alone or with etoposide has been used in patients with recurrent disease who did not receive topotecan initially.[28][Level of evidence A2]

Sources: 28 · Level of evidence A2

Topotecan in combination with cyclophosphamide alone or with etoposide has been used in patients with recurrent disease who did not receive topotecan initially.[28][Level of evidence A2]

The response rates were 32% (18 of 57) for patients who received topotecan and cyclophosphamide and 19% (11 of 59) for patients who received topotecan alone.

In the BEACON trial, patients were randomly assigned to receive either temozolomide or topotecan and temozolomide, with or without bevacizumab.[26]

Sources: 26

In the BEACON trial, patients were randomly assigned to receive either temozolomide or topotecan and temozolomide, with or without bevacizumab.[26]

Response rates were similar in the two treatment groups (23% with temozolomide vs. 27% with topotecan and temozolomide).

The 1-year PFS rate was nominally higher in patients who received topotecan and temozolomide (47%) than in patients who received temozolomide (23%; HR, 0.59; 95% CI, 0.33–1.08).

High-dose carboplatin, irinotecan, and/or temozolomide has been used to treat patients with refractory disease or new relapses (after treatment that included topotecan) occurring off therapy (68% objective response rate). However, this regimen is not used to treat patients whose disease progresses while on therapy.[48]

Sources: 48

A range of other immunotherapy approaches have been used in patients with relapsed neuroblastoma. Single-agent anti-GD2 monoclonal antibody therapy has shown activity in this setting. For example, a phase II trial evaluated a 10-day, long-term infusion of dinutuximab in 40 children with relapsed or refractory high-risk neuroblastoma. The study reported an objective response rate of 26%. This approach was tolerable, with no grade 4 or grade 5 events.[49]

Sources: 49

Allogeneic transplant has a historically low success rate in recurrent or progressive neuroblastoma. In a retrospective registry study, allogeneic HSCT after a previous autologous HSCT appeared to offer no benefit. Disease recurrence remains the most common cause of treatment failure.[50] A similar conclusion was reached in a multicenter phase II trial of reduced-intensity conditioning allogeneic HSCT in 51 patients, 44 of whom had relapsed or refractory high-risk neuroblastoma. The 5-year disease-free survival (DFS) rate was 11.8%.[51]

Sources: 50 · 51

The use of GD2-directed therapy after haploidentical transplant may be a more promising strategy. In one trial of 68 patients with relapsed neuroblastoma, the use of dinutuximab and subcutaneous interleukin-2 after haploidentical transplant was feasible, with a low rate of graft-versus-host disease. The 5-year EFS rate was 43%. Superior outcomes were obtained for patients who had complete or partial responses at the start of dinutuximab therapy. Among patients with disease after transplant, the complete response rate to anti-GD2 immunotherapy was 35%.[52]

Sources: 52

Clinical trials of vaccines designed to induce host antiganglioside antibodies that can replicate the antineoplastic activities of intravenously administered monoclonal antibodies are ongoing. Patients also receive a beta-glucan treatment, which has a broad range of immunostimulatory effects and synergizes with anti-GD2/GD3 monoclonal antibodies. In a phase I study of 15 children with high-risk neuroblastoma, the therapy was tolerated without any dose-limiting toxicity.[53] Long-term PFS has been reported in patients who achieve a second or later complete or very good partial remission followed by consolidation with anti-GD2 immunotherapy and isotretinoin with or without maintenance therapy. This includes patients who had previously received anti-GD2 immunotherapy and isotretinoin.[54]

Sources: 53 · 54

In a phase I/II trial, the use of autologous chimeric antigen receptor (CAR)–expressing T cells directed against GD2 was feasible and safe in treating children with relapsed or refractory, high-risk neuroblastoma. This treatment resulted in a response rate of 63%.[55] These findings contrast with earlier reports that showed only modest activity of other GD2-directed CAR T-cell approaches in this same population.

Sources: 55

Health professional · Treatment of Recurrent or Refractory Neuroblastoma

Recurrent Neuroblastoma in the Central Nervous System

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Central nervous system (CNS) involvement, although rare at initial presentation, may occur in 3% to 10% of patients with recurrent neuroblastoma. CNS relapses represented 6% of all metastatic relapses in a series of 1,161 first relapses in 1,977 patients with stage 4 disease treated in a trial of patients with high-risk neuroblastoma.[56] Because up-front treatment for newly diagnosed patients does not adequately treat the CNS, the CNS has emerged as a sanctuary site leading to relapse.[56-58]

Sources: 56 · 56 · 58

Significant risk factors for CNS relapse identified in the International Society of Paediatric Oncology Europe Neuroblastoma (SIOPEN) trial were patient and disease features at diagnosis. These features included female sex (HR, 2.0; P = .016), MYCN amplification (HR, 2.4; P = .0008), hepatic disease (HR, 2.5; P = .01), or more than one metastatic system/compartment involvement (HR, 7.1; P = .047). Neither high-dose chemotherapy nor immunotherapy was associated with higher risk of recurrence. Investigators noted stable incidence of CNS relapse reported over time.[56]

Sources: 56

CNS relapses are almost always fatal, with a median time to death of 6 months. The 1-year and 3-year postrelapse OS rates were 25% and 7%, respectively, in the SIOPEN trial.[56] Patients with isolated CNS relapses may be able to achieve long-term survival.[56]

Sources: 56 · 56

Treatment options for recurrent neuroblastoma in the CNS include the following:

Surgery and radiation therapy.

Chemotherapy (including temozolomide-containing regimens) in combination with surgery and radiation therapy.

Novel therapeutic approaches.

Current treatment approaches generally include eradicating bulky and microscopic residual disease in the CNS and minimal residual systemic disease that may herald further relapses. Neurosurgical interventions serve to decrease edema, control hemorrhage, and remove bulky tumor before starting therapy.

A single institution had some success while testing intraventricular compartmental radioimmunotherapy using intrathecal radioiodinated anti-B7H3 monoclonal antibodies, combined with 18 Gy or 21 Gy of craniospinal irradiation with boosts to gross CNS disease, in patients with recurrent metastatic CNS neuroblastoma.[13] The posttreatment 5-year CNS DFS rate was about 69%, and the 5-year OS rate was about 45%.[59][Level of evidence C2]

Sources: 13 · 59 · Level of evidence C2

For patients who experience prolonged survival after an initial CNS relapse, some may develop a second relapse after cranial spinal irradiation (CSI). Published data for patients who experience a second CNS relapse are limited. A second CNS relapse indicates a poor prognosis.[57]

Sources: 57

In a single-institution study that included 128 patients treated with CSI for first CNS relapse, 40 developed a second CNS relapse at a median of 6.3 months from the initial CSI treatment. Patient outcomes after second CNS relapse are poor, although treatment with radiation therapy at the time of second CNS relapse may be associated with longer OS.[60][Level of evidence C1]

Sources: 60 · Level of evidence C1

The 1-year survival rate was 32.5%.

Patients in this group with initial leptomeningeal involvement were more likely to relapse than those who had exclusively parenchymal lesions (HR, 2.5; 95% CI, 1.3–4.9; P = .006). The median time to second CNS relapse was 6.8 months, 51% of which occurred outside the CSI boost field.

Most patients (24 of 40) received radiation as part of the multimodality approach for the second CNS relapse. Receipt of radiation therapy at time of second CNS relapse was associated with improved OS (median, 30 vs. 5.1 months; HR, 0.5; log-rank P < .001).

Eight of the 40 patients received compartmental intrathecal radioimmunotherapy (cRIT) with radioiodinated anti-GD2 and/or anti-B7H3 monoclonal antibodies as part of their treatment. The prolonged median OS from the time of second relapse was 22 months for patients who received cRIT. In comparison, the median OS was 5 months for patients who did not receive cRIT. Five of these patients had previously received cRIT at the time of initial CNS relapse.

Health professional · Treatment of Recurrent or Refractory Neuroblastoma

Treatment Options Under Clinical Evaluation for Recurrent or Refractory Neuroblastoma

Source: Neuroblastoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 28, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

ADVL1621 (NCT02332668) (A Phase I/II Study of Pembrolizumab [MK-3475] in Children With Advanced Melanoma or a PD-L1–Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma): Part 1 of this study will find the maximum tolerated dose, confirm the dose, and find the recommended phase II dose for pembrolizumab therapy. Part 2 of the study will further evaluate the safety and efficacy at the pediatric phase II recommended dose.

Sources: ADVL1621 (NCT02332668)

For patients · General Information About Neuroblastoma

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

If your child has been diagnosed with neuroblastoma, you may have questions about how serious the cancer is and your child's chances of survival. The likely outcome or course of a disease is called prognosis.

Sources: prognosis

The prognosis and treatment options depend on:

age at the time of diagnosis

the child's risk group

Sources: risk group

whether there are certain changes in the MYCN or ALK genes

whether the tumor is diploid or hyperdiploid

Sources: diploid · hyperdiploid

whether there are changes to the tumor chromosomes

the type of tumor neurotrophin receptor

Sources: receptor

where in the body the tumor started (abdomen, chest, neck, or spine)

Sources: spine

the stage of the cancer

Sources: stage

levels of LDH and ferritin

how the tumor responds to treatment

how much time passed between diagnosis and when the cancer recurred (for recurrent cancer)

Sources: recurred · recurrent cancer

Prognosis and treatment options for neuroblastoma are also affected by tumor histology, which includes:

Sources: histology

the patterns of the tumor cells

how different the tumor cells are from normal cells

how fast the tumor cells are growing

The tumor histology is said to be favorable or unfavorable, depending on these factors. A child with favorable tumor histology has a better chance of recovery.

Sources: recovery

In some children up to age 6 months, neuroblastoma may disappear without treatment. This is called spontaneous regression. The child is closely watched for signs or symptoms of neuroblastoma. If signs or symptoms occur, treatment may be needed.

Sources: regression

For patients · Stages of Neuroblastoma

Treatment of neuroblastoma is based on risk groups.

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

For many types of cancer, stages are used to plan treatment. For neuroblastoma, treatment depends on the patient's risk group. The risk group is determined by the following factors:

Sources: risk group

the stage of the cancer

the child's age at diagnosis

the International Neuroblastoma Pathologic Classification (INPC) (tumor histology)

Sources: histology

whether the tumors are diploid or hyperdiploid (DNA index)

Sources: DNA index

whether the cancer gene MYCN is found in the tumor cells

how much of the cancer could be removed by surgery

There are three risk groups: low risk, intermediate risk, and high risk.

Low-risk and intermediate-risk neuroblastoma have a good chance of being cured.

Sources: cured

High-risk neuroblastoma may be hard to cure.

For more information on the risk group classification, see the Revised International Neuroblastoma Response Criteria (INRC) section in Neuroblastoma Treatment (Health Professional Version).

Sources: Revised International Neuroblastoma Response Criteria

For patients · Stages of Neuroblastoma

Sometimes neuroblastoma does not respond to treatment or comes back after treatment.

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

Refractory neuroblastoma is a tumor that does not respond to treatment.

Sources: Refractory · respond

Recurrent neuroblastoma is cancer that has recurred (come back) after it has been treated. The tumor may come back in the site where it began or in the central nervous system.

Sources: Recurrent · recurred · central nervous system

For patients

Treatment Option Overview

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

There are different types of treatment for children with neuroblastoma.

Children with neuroblastoma should have their treatment planned by a team of doctors who are experts in treating childhood cancer, especially neuroblastoma.

The following types of treatment may be used:

The following types of treatment may be used:

Observation

Surgery

Chemotherapy

Radiation therapy

High-dose chemotherapy and radiation therapy with stem cell rescue

Iodine 131-MIBG therapy

Targeted therapy

Other drug therapy

Immunotherapy

New types of treatment are being tested in clinical trials.

Treatment for neuroblastoma causes side effects and late effects.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for children with neuroblastoma.

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

There are different types of treatment for children and adolescents with neuroblastoma. You and your child's cancer team will work together to decide treatment. Many factors will be considered, such as your child's overall health and whether the cancer is newly diagnosed or has come back.

Sources: neuroblastoma

For patients · Treatment Option Overview

Children with neuroblastoma should have their treatment planned by a team of doctors who are experts in treating childhood cancer, especially neuroblastoma.

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

A pediatric oncologist, a doctor who specializes in treating children with cancer, will oversee treatment. The pediatric oncologist works with other pediatric health care professionals who are experts in treating children with cancer and who specialize in certain areas of medicine. These may include the following specialists and others:

Sources: pediatric oncologist

pediatric surgeon

Sources: pediatric surgeon

pediatric radiation oncologist

Sources: radiation oncologist

endocrinologist

Sources: endocrinologist

neurologist

Sources: neurologist

pediatric neuropathologist

Sources: neuropathologist

neuroradiologist

Sources: neuroradiologist

pediatrician

Sources: pediatrician

pediatric nurse specialist

Sources: pediatric nurse specialist

social worker

Sources: social worker

child life professional

Sources: child life professional

psychologist

Sources: psychologist

Your child's treatment plan will include information about the cancer, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's cancer care team before treatment begins about what to expect. For help every step of the way, see our downloadable booklet, Children with Cancer: A Guide for Parents.

Sources: treatment plan · side effects · Children with Cancer: A Guide for Parents

For patients · Treatment Option Overview

The following types of treatment may be used:

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment may be used:

Observation

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

Observation is closely monitoring a patient's condition without giving any treatment until signs or symptoms appear or change.

Sources: monitoring · signs · symptoms

For patients · Treatment Option Overview / The following types of treatment may be used:

Surgery

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

Surgery is used to treat neuroblastoma that has not spread to other parts of the body. As much of the tumor as is safely possible is removed. Lymph nodes are also removed and checked for signs of cancer.

Sources: Lymph nodes

If the tumor cannot be removed, a biopsy may be done instead.

Sources: biopsy

Learn more about Surgery to Treat Cancer.

Sources: Surgery to Treat Cancer

For patients · Treatment Option Overview / The following types of treatment may be used:

Chemotherapy

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).

Sources: Chemotherapy · injected · systemic chemotherapy

The use of two or more anticancer drugs is called combination chemotherapy.

Sources: anticancer · combination chemotherapy

See Drugs Approved for Neuroblastoma for more information.

Sources: Drugs Approved for Neuroblastoma

Learn more about Chemotherapy to Treat Cancer.

Sources: Chemotherapy to Treat Cancer

For patients · Treatment Option Overview / The following types of treatment may be used:

Radiation therapy

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are different types of radiation therapy:

Sources: Radiation therapy · x-rays · radiation

External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. This treatment is used for patients with high-risk neuroblastoma or for patients whose tumor grew while being treated with chemotherapy.

Sources: External radiation therapy

Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.

Sources: Internal radiation therapy · radioactive · seeds · catheters

Radioimmunotherapy is a type of radiation therapy in which a radioactive substance is linked to a monoclonal antibody and injected into the body. The monoclonal antibody can bind to substances in the body, including cancer cells. The radioactive substance gives off radiation, which may help kill cancer cells.

Sources: Radioimmunotherapy · monoclonal antibody

Learn more about Radiation Therapy to Treat Cancer.

Sources: Radiation Therapy to Treat Cancer

For patients · Treatment Option Overview / The following types of treatment may be used:

High-dose chemotherapy and radiation therapy with stem cell rescue

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

High-dose chemotherapy and radiation therapy are given to kill any cancer cells that may regrow and cause the cancer to come back. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell rescue is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient and are frozen and stored. After the completion of chemotherapy and radiation therapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.

Sources: High-dose chemotherapy · blood · Stem cell rescue · Stem cells · bone marrow · infusion

For patients · Treatment Option Overview / The following types of treatment may be used:

Iodine 131-MIBG therapy

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

Iodine 131-MIBG therapy is a treatment with radioactive iodine. The radioactive iodine is given through an intravenous (IV) line and enters the bloodstream, which carries radiation directly to tumor cells. Radioactive iodine collects in neuroblastoma cells and kills them with the radiation that is given off. Iodine 131-MIBG therapy is sometimes used to treat high-risk neuroblastoma that comes back after initial treatment.

Sources: Iodine 131-MIBG · therapy · radioactive iodine · intravenous

For patients · Treatment Option Overview / The following types of treatment may be used:

Targeted therapy

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

Targeted therapy uses drugs or other substances to block the action of specific enzymes, proteins, or other molecules involved in the growth and spread of cancer cells.

Sources: Targeted therapy · enzymes · proteins · molecules

Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.

Sources: immune system · toxins · radioactive

Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.

Dinutuximab is used to treat patients with high-risk neuroblastoma and neuroblastoma that has come back after treatment or has not responded to treatment.

Sources: Dinutuximab

Ornithine decarboxylase inhibitor therapy slows the growth and division of cancer cells.

Ornithine decarboxylase inhibitor therapy slows the growth and division of cancer cells.

Eflornithine may be given for two years after maintenance therapy for high-risk neuroblastoma.

Sources: Eflornithine

Learn more about Targeted Therapy to Treat Cancer.

Sources: Targeted Therapy to Treat Cancer

For patients · Treatment Option Overview / The following types of treatment may be used:

Other drug therapy

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

Other drugs used in combination to treat neuroblastoma include:

Isotretinoin: A vitamin-like drug that slows the cancer's ability to make more cancer cells and changes how these cells look and act. This drug is taken by mouth.

Sources: Isotretinoin

For patients · Treatment Option Overview / The following types of treatment may be used:

Immunotherapy

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

Immunotherapy helps a child's immune system fight cancer.

Sources: Immunotherapy

Granulocyte-macrophage colony-stimulating factor (GM-CSF): a cytokine that helps the body make more white blood cells, especially granulocytes and macrophages, which can attack and kill cancer cells. GM-CSF can also enhance the immune system response against cancer by increasing the number of cancer-fighting T cells.

Sources: Granulocyte-macrophage colony-stimulating factor · cytokine · white blood cells · granulocytes · macrophages · T cells

CAR T-cell therapy: The patient's T cells (a type of immune system cell) are changed so that they will attack certain proteins on the surface of cancer cells. T cells are taken from the patient, and special receptors are added to their surface in the laboratory. The changed cells are called chimeric antigen receptor (CAR) T cells. The CAR T cells are grown in the laboratory and given to the patient by infusion. The CAR T cells multiply in the patient's blood and attack cancer cells. CAR T-cell therapy is being studied to treat neuroblastoma that has come back after treatment or has not responded to treatment.

Sources: CAR T-cell therapy · proteins · receptors · chimeric antigen receptor

Learn more about T-Cell Transfer Therapy.

Sources: T-Cell Transfer Therapy

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for people with cancer. For some patients, taking part in a clinical trial may be an option. Because cancer in children is rare, taking part in a clinical trial should be considered.

Sources: clinical trial · research study

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. Some clinical trials are open only to patients who have not started treatment. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · NCI · ClinicalTrials.gov

Learn more at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Treatment Option Overview

Treatment for neuroblastoma causes side effects and late effects.

Source: Neuroblastoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 23, 2024. Captured 2026-09-09.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:

Sources: late effects

physical problems, such as:

physical problems, such as:

tooth development

intestinal blockage (obstruction)

Sources: intestinal · obstruction

bone and cartilage growth

Sources: cartilage

hearing function

metabolic syndrome (elevated blood pressure, elevated triglycerides, elevated cholesterol, increased body fat percentage)

Sources: metabolic syndrome · blood pressure · cholesterol

changes in mood, feelings, thinking, learning, or memory

second cancers (new types of cancer), such as myelodysplastic syndrome, acute myeloid leukemia, thyroid cancer, or kidney cancer

Sources: second cancers · myelodysplastic syndrome · acute myeloid leukemia · thyroid cancer · kidney cancer

Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. Learn more about Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer